Photo of Clinical Research Volunteers
Office of the Vice President for Research
FindAStudy :: Human Studies @ UTHSCSA
150  Studies 83  Researchers 24  Categories
× Server Error: Please contact a VPR IT team member for assistance.
× Result: 0 studies found using ""
No studies found - try again with different search terms.
Choose a Category Below to Show a List of Study Titles
  •   Aging and Geriatric

    •   Effect of mTOR Inhibition and other Metabolism Modulating Interventions on...
      Protocol No.
      HSC20120304H
      Official Title
      Effect of mTOR Inhibition and other Metabolism Modulating Interventions on the Elderly: Immune, Cognitive, and Fuctional Consequences.
      Description
      A research study of the mechanisms that are affected by the mTOR inhibition by Rapamycin. Rapamycin is a drug approved by the US Food and Drug Administration (FDA) for human use that has shown to increase lifespan in laboratory animals. In human medicine, Rapamycin is used is an immunosuppressant drug used to prevent rejection in organ transplantation; it is especially useful in kidney transplants. mTOR controls growth of cells in your body. Rapamycin reduced mTOR effects. The researchers hope to learn how mTOR inhibition affects humans by looking at how the immune system that is altered in normal aging and mTOR inhibition by Rapamycin. The information gained from these experiments will aid in understanding how mTOR inhibition works in humans and will provide new and important information on changes in age-related immune system regulation.
      Contact
      210-497-7279
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Human Innate Immunity and Tuberculosis
      Protocol No.
      HSC20170315H
      Official Title
      Human Innate Immunity and Tuberculosis
      Description
      Tuberculosis is an infection that primarily affects the lungs and causes fever and weight loss. While some people exposed to the tuberculosis (TB) bacteria develop the disease others do not. An important step in our understanding of these different responses is to measure the response of immune cells to infection with the TB bacteria. This study will request blood to be collected from healthy individuals and individuals who have had a positive test result for TB.
      Contact
      (210) 258-9577
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Long-Term Nicotine Treatment of Mild Cognitive Impairment
      Protocol No.
      HSC20180378H
      Official Title
      Long-Term Nicotine Treatment of Mild Cognitive Impairment
      Description
      Long-Term Nicotine Treatment of Mild Cognitive Impairment There is some evidence that nicotine interacts with the brain cells involved in memory and attention. Difficulty in these areas can be symptoms of Mild Cognitive Impairment (MCI). This clinical trial seeks to enroll individuals with MCI to determine if nicotine, delivered via patch, is helpful in improving memory when compared to placebo. The Biggs Institute is one of several sites enrolling participants in this study. Eligible participants will be between 55-90 years old, with mild memory problems, that they, their loved one, or a doctor have noticed. Participants will need to identify a study partner who can come to every clinic visit with them. Interested individuals must speak English fluently, and have no history of tobacco or nicotine use within the last year.
      Contact
      210-567-8229
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Metformin and vaccine response in older adults
      Protocol No.
      HSC20180171H
      Official Title
      Metformin and vaccine response in older adults
      Description
      Older adults’ immune systems will weaken with age. Over time, it becomes more difficult to mount an adequate immune response to vaccines to protect against subsequent infections, such as pneumonia. This study will provide information on whether a treatment with metformin will improve ‘pneumonia’ vaccine responses in older adults. Participants will be followed for 3 months.
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   NF-Kappa B Activation by NADPH Oxidases
      Protocol No.
      HSC19949484H
      Official Title
      NF-Kappa B Activation by NADPH Oxidases (Project of a program entitled "Nuclear Factor Kappa B, Oxidative Stress and Aging)
      Description
      This study is a research project on the antibacterial function of white blood cells. We hope to learn how white blood cells work to prevent infection and how they respond after infection occurs.
      Contact
      210-562-4010
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Study of gait patterns and memory changes
      Protocol No.
      HSC20190066H
      Official Title
      Multi-dimensional Assessment of Gait and Cognition Study: GaitIQ
      Description
      We are studying how the brain function of an older person affects the way he or she walks (gait). We are seeking participants over 65 with worsening memory (but no diagnosis of dementia) or difficult walking or climbing stairs. Results will help understand whether gait analysis can identify dementia risk.
      Contact
      210-450-8419
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Targeted Removal of Pro-Inflammatory Cells: an open label human pilot study...
      Protocol No.
      HSC20170199H
      Official Title
      Targeting Pro-Inflammatory Cells in Idiopathic Pulmonary Fibrosis: a Human Trial
      Description
      To reduce the abundance of pro-inflammatory cells over baseline within subjects following treatment with dasatinib and quercetin
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Using Metformin to Prevent Frailty in Older Patients who have Pre-Diabetes
      Protocol No.
      HSC20150237H
      Official Title
      Metformin for Preventing Frailty in High-risk Older Adults
      Description
      Many older adults will become frail with age. Older adults with pre-diabetes are at the highest risk of becoming frail. This study will provide information on whether treatment with metformin will delay or prevent the onset of frailty. Participants will be followed for two years.
      Contact
      210-617-5190
      Locations
      UT Health Science Center
      Learn More About This Study

       

  •   Behaviors and Mental Disorders

    •   A Pilot Study of the Treatment for Trauma-Related Nightmares
      Protocol No.
      HSC20150396H
      Official Title
      A Pilot Randomized Controlled Trial of Treatment for Trauma-Related Nightmares In Active Duty Military Personnel
      Description
      The researchers hope to learn if a behavioral treatment for nightmares can significantly reduce nightmare frequency, nightmare severity, sleep problems, depression and anxiety in active duty military personnel. Eligible participants are active duty military personnel with Nightmare Disorder who are stationed at Fort Hood, Texas.
      Contact
      254-288-1360
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Brief treatment for Posttraumatic Stress Disorder: Enhancing treatment...
      Protocol No.
      HSC20150904H
      Official Title
      Brief Treatment for Posttraumatic Stress Disorder: Enhancing Treatment Engagement and Retention
      Description
      The purpose of this study is to investigate whether a brief written treatment for PTSD is equally effective as a more intensive treatment. Written Exposure Therapy (WET) is a brief, trauma-focused treatment that involves writing about your traumatic experiences. Cognitive Processing Therapy (CPT) is a more intensive, trauma-focused treatment that involves learning to recognize and challenge thoughts related to your traumatic experiences. Eligible participants are active duty military presonnel with PTSD who have deployed since 9/11 and who are stationed in the San Antonio area.
      Contact
      210-562-6726
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Clinical Effectiveness Trial of In-Home Cognitive Processing Therapy for...
      Protocol No.
      HSC20140055H
      Official Title
      Clinical Effectiveness Trial of In-Home Cognitive Processing Therapy for Combat-Related PTSD
      Description
      This STRONG STAR research study will examine effective ways of delivering Cognitive Processing Therapy (CPT) for combat-related posttraumatic stress disorder (PTSD). CPT involves learning to recognize and challenge thoughts related to a traumatic experience and is typically done through face-to-face sessions in a mental health clinic. However, traveling into a clinic can be a potential barrier for some people. The goal of this study is to evaluate the effectiveness of administering CPT in one of the following treatment settings: 1) face-to-face in a clinic office, 2) face-to-face in the home setting, or 3) through telehealth (i.e., video sessions on your computer) in the home setting. Eligible participants are OIF/OEF/OND veterans with PTSD who reside in the San Antonio area.
      Contact
      210-562-6727
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Computer Based Training in Cognitive Behavioral Therapy for Spanish-Speaking...
      Protocol No.
      HSC20160575H
      Official Title
      Computer Based Training in CBT for Spanish-Speaking Substance Users
      Description
      We are seeking Spanish speaking individuals currently in or seeking treatment for substance use. The purpose of this study is to test the effectiveness of adding a computer delivered web-based form of Cognitive Behavioral Therapy to treatment currently being received. You will be asked to attend approximately 12 visits with the researchers or study staff at UTHSCSA, in addition to 8 weekly treatment visits and encounters. If you are assigned to the CBT4CBT group, there will be up to 8 additional encounters on a web-based platform. These modules may be completed on your own time by logging in to the web-based platform (cbt4cbt.com) and will take approximately one hour to complete. Most people complete one module per week, and you may choose the order in which you complete them. It may be necessary for you to return to the hospital/clinic every week and after the treatment period, for 2 follow up visits.
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Functional neuroanatomy of social and perceived internal threat in anxious...
      Protocol No.
      HSC20170149H
      Official Title
      Functional neuroanatomy of social and perceived internal threat in anxious youth at high-risk for bipolar disorder
      Description
      We are looking for children ages 8-17 who are anxious or worry a lot AND who have a biological parent with Bipolar Disorder. We are also looking for healthy families in which the parents and child have not received psychiatric diagnoses. Mental health assessments and MRI will be completed.
      Contact
      210-450-8362
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Identifying and Validating Complex Comorbidity Clusters in OEF-OIF Veterans
      Protocol No.
      HSC20100395H
      Official Title
      Trajectories of Resilience and Comorbidity Clusters in OEF-OIF Veterans (TRACC) Traumatic Brain Injury (TBI)
      Description
      The purpose of this study is to examine the kinds of health conditions that occur together (comorbidity clusters) in Veterans of wars in Afghanistan and Iraq (OEF/OIF) over time, and the types of experiences during military service and after military service that may be associated with these patterns.
      Contact
      210-617-5314
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Improvements in Brain Function during Psychotherapy For Teens with Symptoms...
      Protocol No.
      HSC20160637H
      Official Title
      Improvements in Brain Function during Psychotherapy For Teens with Posttraumatic Stress
      Description
      The purpose of the study is to analyze how brain functioning improves when symptoms of posttraumatic stress improve during psychotherapy. Teens who have experienced trauma and are bothered by symptoms of stress will be provided with the ‘gold-standard’ psychotherapy for trauma, at no-cost. They will have brain scans using Magnetic Resonance Imaging (MRI) before, during, and after the treatment: a total of 4 brain scans over the 20-week treatment. MRI is safe and does not use radiation or injections.
      Contact
      210-567-8162
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Maternal Opioid Morbidity Study (MOMS)
      Protocol No.
      HSC20160688H
      Official Title
      Maternal Opioid Morbidity Study (MOMS)
      Description
      Overdose by “ingestion of drugs” is the second leading cause of maternal mortality in the state of Texas. Maternal mortality is defined by the Centers for Disease Control and Prevention as a death occurring during pregnancy or within the first 365 days following the end of a pregnancy. Maternal overdose death in Texas is second only to maternal deaths caused by a cardiac event. Case records (including postmortem toxicology and police reports) indicate that most of these deaths involve the use of licit or illicit prescription opioids; however, little is known about the context of maternal overdose death. Therefore, we are recruiting women who have experienced an opioid use relapse and/or overdose as well as family members, friends and the significant others of women who died of a maternal overdose. We will be conducting private interviews and small group discussions to gain more insight into the circumstances that contribute to maternal overdose.
      Contact
      210-450-8161
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Network Dysregulation Among Individuals with Co-Morbid Tinnitus and PTSD
      Protocol No.
      HSC20180524H
      Official Title
      Network Dysregulation Among Individuals with Co-Morbid Tinnitus and PTSD
      Description
      The purpose of this study is to determine the overlap of symptoms between posttraumatic stress disorder (PTSD) and tinnitus-related distress (ringing or buzzing in one or both ears). We will evaluate the overlap of symptoms by conducting assessments for psychological problems and tinnitus, as well as evaluate brain activity while undergoing a functional magnetic resonance imaging session (MRI). We also would like to know whether alleviating symptoms of PTSD would help decrease bothersome tinnitus. Everyone in this study will be treated for their PTSD with CPT. We will examine if tinnitus-related distress can also be decreased as a function of receiving therapy for PTSD, which is the focus of this study. The researchers hope to learn how the brain connectivity changes for male Veterans with both PTSD and tinnitus, after receiving therapy for PTSD.
      Contact
      210-562-6716
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Project Remission: Maximizing Outcomes with Intensive Treatments for...
      Protocol No.
      HSC20160422H
      Official Title
      Project Remission: Maximizing Outcomes with Intensive Treatments for Combat-Related PTSD
      Description
      The purpose of this study is to examine whether 15 sessions of Massed-Prolonged Exposure (Massed-PE) delivered over 3-weeks is as effective as 15 days of an Intensive Outpatient Prolonged Exposure protocol (IOP-PE) delivered over 3-weeks in the treatment of combat-related PTSD. The researchers hope to learn if these programs improve treatment accessibility, patient retention, and treatment outcomes. Eligible participants are veterans and active duty military personnel with PTSD who have deployment since 9/11 and who are stationed in the San Antonio, Fort Hood, and Waco, Texas areas.
      Contact
      210-562-6726
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   The Impact of Prenatal Opioid Use on Maternal-Infant Dyad
      Protocol No.
      HSC20180057H
      Official Title
      The Impact of Prenatal Opioid Use on Maternal-Infant Dyad
      Description
      Opioid exposure during pregnancy may place babies at risk for developing neonatal abstinence syndrome. The purpose of this study is to explore the impact of prenatal opioid use on stress and physiological attunement in mother-baby dyads. We are recruiting opioid and non-opioid using pregnant women.
      Contact
      210-450-8294
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Tooth Fairy Study
      Protocol No.
      HSC20110313H
      Official Title
      Potential Risk Factors Associated with Autism Spectrum Disorders
      Description
      Participate in the Tooth Fairy Study! Our research team recently discovered that toxins such as plastics, pesticides and medications are stored in baby teeth as they are forming during pregnancy and shortly thereafter. The cause of autism is unknown; however, genetic and environmental factors are both likely involved. This study is being done to learn if children with autism have been exposed to more environmental toxins than typically-developing children and to learn if their genes are more vulnerable to the toxins. We are currently enrolling biological mothers of children with autism, their siblings AND mothers of children developing normally. Participants will fill out a survey regarding nutrition and exposures (~30 minutes), and donate their child’s baby teeth. To be eligible for this study… • You must be the biological mother of a child who is 2 years or older. • Your child must either have an established or suspected diagnosis of autism OR be a typically-developing child with no chronic medical problems • You must have a tooth from your child in good condition (not too worn or large cavities/crowns) To learn more about this study… Contact Lynne Heilbrun, MPH at heilbrun@UTHSCSA.edu.
      Contact
      210-274-4009
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Understanding the genetics of bipolar I disorder in adolescents
      Protocol No.
      HSC20150334H
      Official Title
      Application of induced pluripotent stem cells for the study of bipolar I disorder
      Description
      The purpose of this research is to develop a cell-based system to study adolescent bipolar I disorder to better understand genetic and epigenetic mechanisms associated with risk and develop new methods for treatment. We will perform MRI, neurocognitive and neuropsychiatric testing and draw blood.
      Contact
      210-258-9766
      Locations
      UT Health Science Center
      Learn More About This Study

       

  •   Cancers and Other Neoplasms

    •   Bones and joints

      •   Effects of Modern Chemotherapy Regimens on Spermatogenesis and...
        Protocol No.
        HSC20180743XT
        Official Title
        Effects of Modern Chemotherapy Regimens on Spermatogenesis and Steroidogenesis in Adolescent and Young Adult (AYA) Survivors of Osteosarcoma (CTMS# 18-0146)
        Description
        Determine whether infertility and/or biomarkers of spermatogenesis and steroidogenesis differ in male osteosarcoma survivors treated with cisplatin with or without ifosfamide compared to male controls without a history of cancer. Evaluate whether cisplatin with or without ifosfamide for the treatment of osteosarcoma alters sperm deoxyribonucleic acid (DNA) methylation.
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

    •   Brain & Nervous System

      •   A Phase 2 Investigator Initiated Study to Determine the Efficacy and Safety...
        Protocol No.
        HSC20170090HU
        Official Title
        A Phase 2 Investigator Initiated Study to Determine the Efficacy and Safety of TVB-2640 in Combination with Bevacizumab in Patients with First Relapse of High Grade Astrocytoma (CTMS# 16-0136)
        Description
        Primary Objective(s): To determine if the progression-free survival of patients with High Grade Astrocytoma who are treated with TVB-2640 in combination with bevacizumab is superior to treatment with bevacizumab alone. Secondary Objective(s): To evaluate the safety of TVB-2640 in combination with bevacizumab in patients with High Grade Astrocytoma. Exploratory Objective: To determine the extent by which TVB-2640 is able to penetrate the blood brain barrier where it might have the opportunity to affect tumor tissue metabolism.
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk...
        Protocol No.
        HSC20170671XT
        Official Title
        A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients (CTMS# 17-0157)
        Description
        PFS
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or Crizotinib...
        Protocol No.
        HSC20180742XT
        Official Title
        A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or Crizotinib Added to Intensive Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma (NBL) (CTMS# 18-0144)
        Description
        To determine in the context of a randomized trial whether the EFS of patients with newly diagnosed high-risk NBL is improved with the addition of 131I-MIBG during Induction, prior to tandem autologous stem cell transplantation (ASCT).
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   An Expanded Access Extension of A Phase 3, Randomized, Controlled,...
        Protocol No.
        HSC20180547XT
        Official Title
        An Expanded Access Extension of A Phase 3, Randomized, Controlled, Double-Arm, Open-Label, Multi-Center Study of VB-111 Combined with Bevacizumab vs. Bevacizumab Monotherapy in Patients with Recurrent Glioblastoma (CTMS#18-0090)
        Description
        Single patient treatment study with VB-111 + Bevacizumab
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   An Expanded Access Extension of A Phase I/II Single-Arm Open-Label...
        Protocol No.
        HSC20180548TX
        Official Title
        An Expanded Access Extension of A Phase I/II Single-Arm Open-Label Multicenter Study of VB-111 in Patients with Recurrent Glioblastoma Multiforme (CTMS#18-0089)
        Description
        Single patient expanded access treatment with VB-111
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   An Open-Label Non-Randomized, Multi-Center Phase-2 Study of...
        Protocol No.
        HSC20160689HU
        Official Title
        An Open-Label Non-Randomized, Multi-Center Phase-2 Study of Convection-Enhanced Delivery (CED) of MDNA55 in Adults with Glioblastoma at First Recurrence or Progression (CTMS# 16-0088)
        Description
        Primary To determine the objective response rate (ORR) per iRANO criteria following intra- and peritumoral infusion using CED of MDNA55 in adult subjects with GB at first recurrence following standard therapy Secondary To assess the safety of MDNA55 following CED in adult subjects with GB at first recurrence following standard therapy. To assess overall survival (OS) in these subjects To assess progression-free survival (PFS; using iRANO criteria) in these subjects Exploratory To assess the pharmacokinetics (PK) of MDNA55 in peripheral plasma as measured by enzyme-linked immunosorbent assay (ELISA) To assess anti-MDNA55 antibody titer and, if anti-MDNA55 titer is observed, determine neutralizing antibody titer and its effect on the safety and efficacy of MDNA55 To perform additional ad hoc efficacy and safety analyses as needed based on the data acquired in this study
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   EAF151: Change in Relative Cerebral Blood Volume as a Biomarker for Early...
        Protocol No.
        HSC20170313HU
        Official Title
        EAF151: Change in Relative Cerebral Blood Volume as a Biomarker for Early Response to Bevacizumab in Patients with Recurrent Glioblastoma (CTMS# 17-0041)
        Description
        Primary Aims To determine whether binary changes (increase vs. decrease) in normalized rCBV within enhancing tumor from baseline to 2 weeks after initiation of anti-angiogenic therapy is associated with overall survival (OS).
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   LEAHRN (Late Effects After High-Risk Neuroblastoma) Study (CTMS# 18-0050)
        Protocol No.
        HSC20180274XT
        Official Title
        LEAHRN (Late Effects After High-Risk Neuroblastoma) Study (CTMS# 18-0050)
        Description
        To estimate the prevalence of organ dysfunction, subsequent malignant neoplasm (SMN), growth impairment, abnormal pubertal development, and neurobehavioral dysfunction in a large cohort of representative 5-year survivors of high-risk neuroblastoma treated with modern therapy. To identify the demographic, clinical and treatment-related risk factors associated with increased risk of organ dysfunction, SMN, growth impairment, abnormal pubertal development and neurobehavioral dysfunction in long-term survivors of high-risk neuroblastoma. To explore the impact of new biologic therapies and diagnostics including immunotherapy, immunocytokines, isotretinoin (cis-retinoic acid) and iobenguane I-131 (131 I-MIBG) on the risk of late effects. To determine the impact of impaired organ function, physical growth, pubertal development, and neurobehavioral function on health-related quality of life (HRQOL) in long-term survivors of high-risk neuroblastoma.
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   PHASE III TRIAL OF OBSERVATION VERSUS IRRADIATION FOR A GROSS TOTALLY...
        Protocol No.
        HSC20180145X
        Official Title
        PHASE III TRIAL OF OBSERVATION VERSUS IRRADIATION FOR A GROSS TOTALLY RESECTED GRADE II MENINGIOMA (CTMS# 18-0016)
        Description
        The primary endpoint is progression-free survival (PFS). The principle objective is to determine the extent of clinical benefit of the addition of adjuvant radiotherapy (RT) to gross total resection (GTR) for patients with newly diagnosed World Health Organization (WHO) grade II meningioma.
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

    •   Breast

      •   A Phase 0, Investigator Initiated Study, Evaluating the Impact of Omega 3...
        Protocol No.
        HSC20160665HU
        Official Title
        A Phase 0, Investigator Initiated Study, Evaluating the Impact of Omega 3 Free Fatty Acid Supplementation on Breast Cancer (CTMS# 16-0119)
        Description
        Primary Objectives Assess the impact of dietary omega 3 FFA: Serum CSF-1 levels patient serum-induced expression of PGE2 by neoplastic mammary epithelial cells, OM3/OM6 circulating levels of pro-inflammatory cytokines (i.e. IL-6, TNF- , IGF-1), steroids (i.e. estrogen and testosterone) and lipids (omega-6 and omega-3 PUFAs) Secondary Objectives Tissue expression of aromatase, CSF1/CSF1R and infiltrating macrophage number and polarity.
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   A Phase II, Multicenter, Open-Label, Two-Cohort, Noncomparative Study to...
        Protocol No.
        HSC20170301HU
        Official Title
        A Phase II, Multicenter, Open-Label, Two-Cohort, Noncomparative Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole in Patients with PIK3CA Mutant, Hormone Receptor (HR) Positive, HER2-Negative Advanced Breast Cancer (aBC), Who Have Progressed On or After CDK 4/6 Inhibitor Treatment (CTMS# 17-0049)
        Description
        Primary Outcome Measures: The percentage of patients who are alive without disease progression Assess the percentage of patients without disease progression based on local investigator assessment per RECIST in cohort A and cohort B
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   A PILOT STUDY OF HYDROXYTYROSOL, A COMPONENT OF OLIVE OIL FOR BREAST CANCER...
        Protocol No.
        HSC20160660HU
        Official Title
        A PILOT STUDY OF HYDROXYTYROSOL, A COMPONENT OF OLIVE OIL FOR BREAST CANCER PREVENTION IN WOMEN AT HIGH RISK OF BREAST CANCER (CTMS# 16-0068)
        Description
        Primary To conduct a pilot breast cancer prevention study of hydroxytyrosol in women at increased risk of breast cancer. To assess whether mammographic density is reduced in pre or post menopausal women at high risk of breast cancer taking hydroxytyrosol for 1 year compared with baseline. Secondary To assess the toxicity of hydroxytyrosol
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   A Randomized Phase II Study of Partial Breast Irradiation and Sequential vs....
        Protocol No.
        HSC20170532HU
        Official Title
        A Randomized Phase II Study of Partial Breast Irradiation and Sequential vs. Concurrent Chemotherapy in Women with Early Stage Breast Cancer (PBI 3.0) (CTMS# 17-0048)
        Description
        Primary Objective Non-inferiority of partial breast irradiation (PBI) and concurrent compared to sequential chemotherapy with respect to acute grade 3-4 radiation toxicity.
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   A study attempting to improve the comfort during screening mammography...
        Protocol No.
        HSC20160392HU
        Official Title
        A study attempting to improve the comfort during screening mammography (CTMS# 16-0045)
        Description
        To determine in a randomized trial whether it is possible to decrease the discomfort and anxiety of mammography by using the local analgesic lidocaine, or by using calming music in patients receiving a mammogram.
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   Alliance A011401 Randomized Phase III Trial Evaluating the Role of Weight...
        Protocol No.
        HSC20160530XT
        Official Title
        Alliance A011401 Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer (CTMS# 16-0082)
        Description
        Primary Objective To compare the effect of a supervised weight loss intervention plus health education materials versus health education materials alone upon invasive disease free survival (iDFS) in overweight (BMI 27-29.9 kg/m2) and obese (BMI 30kg/m2) women diagnosed with HER-2 negative, stage II and III breast cancer. Secondary Objectives To determine the relationship between changes in weight and iDFS, and to explore interaction between the level of clinical benefit from weight loss and the intervention. To evaluate the effect of a supervised weight loss intervention upon: a) Overall survival b) Distant disease free survival c) Weight d) Body composition (as measured by waist and hip circumference) e) Insulin Resistance Syndrome associated conditions diabetes, hospitalization for CV disease To determine the impact of a supervised weight loss intervention on IDFS within subgroups of women with 1) hormone receptor positive breast cancer and 2) hormone receptor negative breast cancer. To determine the impact of a supervised weight loss intervention on IDFS within subgroups of 1) premenopausal women and 2) post-menopausal women.
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   Evaluation of Cryotherapy and TRPA1 Receptors in Chemotherapy Induced...
        Protocol No.
        HSC20170535HU
        Official Title
        Evaluation of Cryotherapy and TRPA1 Receptors in Chemotherapy Induced Neuropathy (CTMS# 17-0033)
        Description
        Specific Aims 1. Evaluate the safety profile and efficacy of cryotherapy in the prevention of peripheral neuropathy during treatment with taxane chemotherapy. 2. Evaluate the safety profile and efficacy of cryotherapy in the prevention of nail toxicity during treatment with taxane chemotherapy. 3. Evaluate the role of TRPA1 in CIPN in patients receiving taxane-based chemotherapy.
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to...
        Protocol No.
        HSC20170531XT
        Official Title
        MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry) (CTMS# 17-0068)
        Description
        Primary Objectives Create a large scale, population-based registry of full genome expression data matched with clinical data to investigate new gene associations with prognostic and/or predictive value Utilize registry data to graduate identified expression signatures into subset trials and recommend interventional trials
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   Phase 1/2, Multicenter, Nonrandomized, Open-Label, Multiple Dose...
        Protocol No.
        HSC20180627XT
        Official Title
        Phase 1/2, Multicenter, Nonrandomized, Open-Label, Multiple Dose First-In-Human Study of U3-1402, In Subject with HER3 Positive Metastatic Breast Cancer (CTMS# 18-0052)
        Description
        Dose Escalation Part To assess the safety and tolerability of U3-1402. To determine the maximum tolerated dose (MTD) of U3-1402. Dose Finding Part To assess the safety and evaluate the efficacy of U3-1402. To determine the recommended dose for expansion (RDE) of U3-1402. Dose Expansion Part To assess the safety and evaluate the efficacy of U3-1402 at the RDE in subjects with HER 2 negative and HR positive breast cancers.
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs....
        Protocol No.
        HSC20160505HU
        Official Title
        Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs. Placebo in Combination with Capecitabine and Trastuzumab in Patients with Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma (HER2CLIMB) (CTMS# 16-0014)
        Description
        Primary Objective To assess the effect of ONT-380 vs. placebo in combination with capecitabine and trastuzumab on bi-compartmental [both central nervous system (CNS) and non-CNS] progression-free survival (PFS) based on independent central review Secondary Objectives To assess the effect of ONT-380 vs. placebo in combination with capecitabine and trastuzumab on bi-compartmental PFS based on investigator assessment To assess the effect of ONT-380 vs. placebo in combination with capecitabine and trastuzumab on PFS, separately in the CNS and non-CNS compartments To assess the effects of ONT-380 vs. placebo in combination with capecitabine and trastuzumab on time to CNS progression To assess the effects of ONT-380 vs. placebo in combination with capecitabine and trastuzumab on objective response rate (ORR), separately in the CNS and non-CNS compartments To assess the duration of response of ONT-380 in combination with capecitabine and trastuzumab, separately in the CNS and non-CNS compartments To assess the clinical benefit rate (CBR) [stable disease (SD) for 6 months, or best response of complete response (CR) or partial response (PR)] of ONT-380 vs. placebo in combination with capecitabine and trastuzumab, separately in the CNS and non-CNS compartments To assess the effects of ONT-380 vs. placebo in combination with capecitabine and trastuzumab on overall survival (OS) To assess the safety and tolerability of ONT-380 in combination with capecitabine and trastuzumab
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   Phase IB/II Open-Label Single Arm Study to Evaluate Safety and Efficacy of...
        Protocol No.
        HSC20170753HU
        Official Title
        Phase IB/II Open-Label Single Arm Study to Evaluate Safety and Efficacy of Tucatinib in Combination with Letrozole and Plabociclib in Subjects with Hormone Receptor Positive and HER2-Positive Metastatic Breast Cancer (CTMS# 17-0138)
        Description
        To evaluate safety and tolerability of tucatinib used in combination with palbociclib and letrozole, and to confirm that current RP2D of tucatinib and FDA approved dosing of palbociclib remain the same in the triplet combination
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   TAILOR RT: A RANDOMIZED TRIAL OF REGIONAL RADIOTHERAPY IN BIOMARKER LOW RISK...
        Protocol No.
        HSC20180650XT
        Official Title
        TAILOR RT: A RANDOMIZED TRIAL OF REGIONAL RADIOTHERAPY IN BIOMARKER LOW RISK NODE POSITIVE BREAST CANCER (CTMS# 18-0110)
        Description
        To compare the breast cancer recurrence-free interval (BCRFI) between patients that received regional RT or not, defined as time from randomization to time of invasive recurrent disease in the ipsilateral chestwall, breast, regional nodes, distant sites or death due to BC.
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   Use of Surface-Image Guidance to Obviate Permanent Tattoos and Verify...
        Protocol No.
        HSC20180769HU
        Official Title
        Use of Surface-Image Guidance to Obviate Permanent Tattoos and Verify Treatment Positioning During Breast Radiotherapy (CTMS# 18-0135)
        Description
        To demonstrate the superiority of radiation therapy localization using specialized light-based surface imaging without the use of permanent tattoos for daily alignment for radiation treatment in women with biopsy-proven ductal carcinoma in-situ (DCIS) or invasive breast cancer who will be receiving radiation therapy postoperatively when compared to the use of temporary skin markings and to historical data of patients aligned with permanent tattoos alone.
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

    •   Colon

      •   A pilot study to evaluate the chemopreventive effects of epigallocatechin...
        Protocol No.
        HSC20160446HU
        Official Title
        A pilot study to evaluate the chemopreventive effects of epigallocatechin gallate (EGCG) in colorectal cancer (CRC) patients with curative resections (CTMS# 16-0085)
        Description
        To evaluate the preventive effects of EGCG on colonic tissue in patients with resected colorectal cancer when compared to patients on observation.
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

    •   Hodgkin Lymphoma

      •   AHOD1331, A Randomized Phase III Study of Brentuximab Vedotin (SGN-35, IND...
        Protocol No.
        HSC20150884XT
        Official Title
        AHOD1331, A Randomized Phase III Study of Brentuximab Vedotin (SGN-35, IND #117117) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Adolescents (CTMS 15-2094)
        Description
        Primary Aims 1.1.1 To assess the event free survival (EFS) of a novel regimen incorporating brentuximab vedotin (Bv; AdcetrisTM) in the chemotherapy backbone of doxorubicin (Adriamycin), vincristine, etoposide, prednisone and cyclophosphamide (Bv-AVEPC) in newly diagnosed high-risk cHL compared to those treated with ABVE-PC. Secondary Aims 1.2.1 To determine whether children/adolescents with high-risk cHL treated with Bv-AVEPC have a higher rate of early response (determined by FDG-PET) and a reduction in response-directed radiation therapy (RT) compared to those treated with ABVE-PC. 1.2.2 To compare the rate of neuropathy (> Grade 3) among patients treated on the Bv-AVEPC (experimental arm) to patients treated on the ABVE-PC (standard arm). Exploratory Aims Childhood International Prognostic Score (CHIPS) 1.3.1 To validate and compare the Childhood Hodgkin International Prognostic Score (CHIPS) to conventional Ann Arbor Stage (Stages II B with bulk, III B, IV A or B) in predicting outcome in high-risk childhood cHL. Biology 1.3.2 To determine the incidence of preferentially expressed antigen in melanoma (PRAME) and testis-specific antigens in EBV- cHL tumors and the incidence of EBV antigens (EBNA1, LMP1, LMP2) in EBV+ cHL tumors, with the goal of developing strategies to integrate cellular therapy into treatment for newly diagnosed high-risk cHL. Imaging 1.3.3 To incorporate qualitative visual FDG-PET into response-directed treatment algorithms and explore quantitative FDG-PET and CT definitions of tumor burden and response for incorporation into next generation pediatric cHL risk-stratification schemes. Radiation Therapy 1.3.4 To evaluate the reduction in normal tissue irradiation associated with the current treatment approach compared to the volume of historic IFRT fields. 1.3.5 To evaluate EFS and patterns of relapse following protocol-specified RT utilization and treatment volumes. Patient Reported Outcomes (PRO) of Peripheral Neuropathy and Health-Related Quality of Life 1.3.6 To characterize the extent of chemotherapy induced peripheral neuropathy (CIPN), as reported by patients and parent proxies, through serial administration of the FACT-GOG-NTX. 1.3.7 To describe the Health-Related Quality of Life (HRQL) consequences of peripheral neuropathy over time by correlating total neuropathy scale scores with the individual items with the CHRIs-Global scale (e.g., physical health, pain, emotional functioning). 1.3.8 To perform a cross validation of the FACT-GOG-NTX with the TNS-PV to determine the performance of both measures with the use of brentuximab vedotin in a limited institutional approach in children and adolescents with cHL (See Appendix VII). Economic (For US Institutions Only) 1.3.9 To assess the resource use and cost implications of Bv in combination with chemotherapy and radiotherapy (RT) for newly diagnosed high-risk cHL in children and adolescents (See Appendix VIII).
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

    •   Kidney

      •   A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of...
        Protocol No.
        HSC20170530XT
        Official Title
        A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (KEYNOTE-564) (CTMS# 17-0032)
        Description
        Primary Objective: To compare DFS as assessed by the investigator for participants treated with pembrolizumab versus those receiving placebo Hypothesis: Pembrolizumab is superior to placebo with respect to DFS. Secondary Objective: To compare OS for participants treated with pembrolizumab versus those receiving placebo Hypothesis: Pembrolizumab is superior to placebo with respect to OS
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   EA8143, A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs....
        Protocol No.
        HSC20170129HU
        Official Title
        EA8143, A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients with Localized Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC) (CTMS# 16-0148)
        Description
        Primary Objectives To compare recurrence-free survival (RFS) between patients with locally advanced renal cell carcinoma randomly assigned to perioperative nivolumab in conjunction with radical or partial nephrectomy with patients randomized to surgery alone. Secondary Objectives To evaluate for differences in recurrence-free survival associated with perioperative nivolumab compared to surgery alone among the subset of patients with clear cell histology. To compare the overall survival between patients randomized to perioperative nivolumab in addition to resection to patients randomized to primary tumor resection alone. To describe the safety and tolerability of perioperative nivolumab
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

    •   Leukemia, other

      •   A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518, IND#133494) in...
        Protocol No.
        HSC20180841XT
        Official Title
        A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518, IND#133494) in Children and Young Adults with Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL) (CTMS# 18-0156)
        Description
        The response rate will be estimated as the percent of eligible and evaluable responders (CR/CRi). A one-sided lower 95% Agresti-Coull confidence limit will be calculated.
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

    •   Liver

      •   A Randomized, Open-label, Multicenter Phase 3 Study to Compare the Efficacy...
        Protocol No.
        HSC20180193XT
        Official Title
        A Randomized, Open-label, Multicenter Phase 3 Study to Compare the Efficacy and Safety of BGB-A317 versus Sorafenib as First-Line Treatment in Patients with Unresectable Hepatocellular Carcinoma (CTMS# 17-0105)
        Description
        Primary: To compare overall survival (OS) between BGB-A317 and sorafenib as first-line treatment in patients with unresectable hepatocellular carcinoma (HCC) To compare objective response rate (ORR) assessed by Blinded Independent Review Committee (BIRC) according to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 between BGB-A317 and sorafenib as first-line treatment in patients with unresectable HCC
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   Hepatocellular Carcinoma Tissue Acquisition (CTMS# 15-2144)
        Protocol No.
        HSC20150834HU
        Official Title
        Hepatocellular Carcinoma Tissue Acquisition (CTMS# 15-2144)
        Description
        Obtain biopsy specimens from Hispanic patients with liver cancer when they come to Radiology clinic for ablation therapy
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   Modulation of Sorafenib induced autophagy using hydroxychloroquine in...
        Protocol No.
        HSC20160515HU
        Official Title
        Modulation of Sorafenib induced autophagy using hydroxychloroquine in hepatocellular cancer (CTMS# 16-0076)
        Description
        Primary Objective(s): To determine the clinical efficacy with to determine the clinical efficacy with time to tumor progression (TTP) of the combination of HCQ and sorafenib in first line advanced HCC (cohort 1); and the addition of HCQ to sorafenib in patients who progress on sorafenib (cohort 2). Secondary Objective(s): To determine the overall survival in advanced HCC patients receiving HCQ and sorafenib in both cohort 1 and 2 To evaluate the tumor response rate in advanced HCC patients receiving HCQ and sorafenib To further define the safety in advanced HCC patients receiving HCQ and sorafenib To identify biomarkers of autophagy modulation and immune markers that correlate with clinical efficacy in advanced HCC patients receiving HCQ and sorafenib.
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   The Texas Hepatocellular Carcinoma Consortium (CTMS# 16-0063)
        Protocol No.
        HSC20160274HU
        Official Title
        The Texas Hepatocellular Carcinoma Consortium (CTMS# 16-0063)
        Description
        The overarching goal of the Texas Hepatocellular Carcinoma Consortium (THCCC), funded by CPRIT Multiple Investigator Research Award (MIRA), is to reduce the burden and mortality of hepatocellular cancer (HCC) in Texas.
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

    •   Lung

      •   Patient-derived organoid model and circulating tumor cells for treatment...
        Protocol No.
        HSC20180485HU
        Official Title
        Patient-derived organoid model and circulating tumor cells for treatment response of lung cancer (CTMS 18-0056)
        Description
        Primary Objective: To establish and characterize a biobank of patient-derived organoids (PDOs), and investigate the potential of PDOs to recapitulate ex vivo responses to chemotherapeutic and targeted agents observed in the clinic.
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

    •   Lymphoid Leukemia

      •   ACCL1333/CV185155A, Phase III Randomized, Open Label, Multi-center Study of...
        Protocol No.
        HSC20150889HU
        Official Title
        ACCL1333/CV185155A, Phase III Randomized, Open Label, Multi-center Study of the Safety and Efficacy of Apixaban for Thromboembolism Prevention versus No Systemic Anticoagulant Prophylaxis during Induction Chemotherapy in Children with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) or Lymphoma (T or B cell) Treated with Pegylated (PEG) L-Asparaginase (CTMS# 15-2044)
        Description
        Primary Objectives: 1)To compare the effect of prophylactic oral or enteric apixaban versus no administration of systemic prophylactic anticoagulant during induction chemotherapy, on the composite endpoint of adjudicated non-fatal deep vein thrombosis (DVT, including symptomatic and asymptomatic), pulmonary embolism (PE), and cerebral venous sinus thrombosis (CVST); and venous thromboembolism (VTE)-related-death during 25-28 days of open-label treatment in pediatric subjects (1 to < 18 years) with newly diagnosed ALL or lymphoma (T or B cell), a functioning central venous access device (CVAD) and receiving PEG L-asparaginase during chemotherapy induction. 2)To assess the effect of prophylactic oral or enteric apixaban versus no administration of systemic prophylactic anticoagulant during induction chemotherapy, on adjudicated major bleeding events during 25 - 28 days of open-label treatment in pediatric subjects (1 to < 18 years) with newly diagnosed ALL or lymphoma (T or B cell), a functioning CVAD and receiving PEG L-asparaginase during chemotherapy induction. Secondary Objectives: 1) To assess the effect of prophylactic oral or enteric apixaban versus no administration of systemic prophylactic anticoagulant during induction chemotherapy, on single adjudicated endpoints of non-fatal DVT (including symptomatic and asymptomatic), PE, and CVST; and VTE-related-death during 25 - 28 days of open-label treatment in pediatric subjects (1 to < 18 years) with newly diagnosed ALL or lymphoma (T or B cell), a functioning CVAD and receiving PEG L-asparaginase during chemotherapy induction. 2) To assess the effect of prophylactic oral or enteric apixaban versus no administration of systemic prophylactic anticoagulant during induction chemotherapy, on the composite endpoint of adjudicated major and clinically relevant non-major bleeding (CRNMB) events during 25 - 28 days of open-label treatment in pediatric subjects (1 to < 18 years) with newly diagnosed acute ALL or lymphoma (T or B cell), a functioning CVAD and receiving PEG L-asparaginase during chemotherapy induction. Other Objectives: 1) To assess the effect of prophylactic oral or enteric apixaban versus no administration of systemic prophylactic anticoagulant during induction chemotherapy, on single adjudicated endpoints of all cause death; arterial thromboembolic events including paradoxical embolism and stroke and CVAD-related infection events during 25 - 28 days of open-label treatment in pediatric subjects (1 to < 18 years) with newly diagnosed ALL or lymphoma (T or B cell), a functioning CVAD and receiving PEG L-asparaginase during chemotherapy induction. 2) To assess the effect of prophylactic oral or enteric apixaban versus no administration of systemic prophylactic anticoagulant during induction chemotherapy, on single adjudicated endpoints of CRNMB and minor bleeding events during 25 - 28 days of open-label treatment in pediatric subjects (1 to < 18 years) with newly diagnosed ALL or lymphoma (T or B cell), a functioning CVAD and receiving PEG L-asparaginase during chemotherapy induction. 3) To assess the effect of prophylactic oral or enteric apixaban versus no administration of systemic prophylactic anticoagulant during induction chemotherapy, on single endpoints of number of catheter replacements needed during the study; events of CVAD dysfunction with improvement after thrombolytic therapy; and number of platelet transfusions during 25 - 28 days of open-label treatment in pediatric subjects (1 to < 18 years) with newly diagnosed ALL or lymphoma (T or B cell), a functioning CVAD and receiving PEG L-asparaginase during chemotherapy induction. 4) To assess the pharmacokinetics of oral or enteric apixaban in pediatric subjects receiving induction chemotherapy for ALL or lymphoma (T or B cell), using a population pharmacokinetic (PPK) approach. 5) To characterize the relationship between apixaban plasma concentration and anti-FXa activity in pedi
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   INCB 18424-269 (COG AALL1521), A Phase 2 Study of the JAK1/JAK2 Inhibitor...
        Protocol No.
        HSC20160625HU
        Official Title
        INCB 18424-269 (COG AALL1521), A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High-Risk CRLF2 Rearranged and/or JAK Pathway-Mutant Acute Lymphoblastic Leukemia (CTMS# 16-0137)
        Description
        Primary Objectives: Part 1 - To evaluate initial safety and tolerability and to define the recommended Part 2 dose (RP2D) of ruxolitinib in combination with multi-agent chemotherapy in children and adolescents or young adults (AYA) with de novo high-risk (HR) Philadelphia chromosome like (Ph-like) cytokine receptor like factor 2 rearranged (CRLF2-R) and/or Janus kinase (JAK) pathway mutant B-cell acute lymphoblastic leukemia (B-ALL). Part 2 - To determine the efficacy of ruxolitinib in combination with chemotherapy for children and AYA with de novo HR Ph-like CRLF2-R and/or JAK pathway mutant B-ALL. Secondary Objective: - To characterize the safety and potential toxicity of ruxolitinib combined with chemotherapy throughout the course of treatment in children and AYA with de novo HR Ph-like CRLF2-R and/or JAK pathway mutant B-ALL. Exploratory Objectives: - To assess the pharmacokinetics (PK) of ruxolitinib in combination with chemotherapy in children and AYA with B-ALL. - To assess rates of minimal residual disease (MRD) at end-Consolidation in end-Induction MRD+ subjects who are treated with ruxolitinib and chemotherapy. - To measure pharmacodynamic (PD) signaling inhibition and biomarkers of ruxolitinib activity, for correlation with ruxolitinib PK and with efficacy measures. - To evaluate the overall survival (OS) of all subjects receiving ruxolitinib in combination with chemotherapy.
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

    •   Myeloid and Monocytic Leukemia

      •   A Phase 2, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety...
        Protocol No.
        HSC20170513XT
        Official Title
        A Phase 2, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Luspatercept (ACE-536) in Subjects with Myeloproliferative Neoplasm-Associated Myelofibrosis and Anemia With and Without Red Blood Cell-Transfusion Dependence (CTMS# 17-0078)
        Description
        The primary objective of this study is: to evaluate the efficacy and safety of luspatercept for the treatment of anemia in subjects with MPN-associated myelofibrosis with and without RBC-transfusion dependence.
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   A Phase Ib Study of Ruxolitinib in Combination with PUH71 for the treatment...
        Protocol No.
        HSC20180153HU
        Official Title
        A Phase Ib Study of Ruxolitinib in Combination with PUH71 for the treatment of Subjects with Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (post-PV MF), and Post-Essential Thrombocythemia MF (post-ET MF) (CTMS# 17-0166)
        Description
        Determine the safety and tolerability, including Dose Limiting Toxicities (DLTs), Maximum Tolerated Dose (MTD), and recommended Phase 2 dose (RP2D) of PU-H71 in combination with ruxolitinib in subjects with PMF, post-PV MF, or post-ET MF with residual signs or symptoms of their disease despite at least 6 months treatment with ruxolitinib (Dose Escalation). Confirm the safety profile and RP2D of PU-H71 in combination with ruxolitinib in this patient population (Dose Confirmation). Determine the pharmacokinetics (PK) of PU-H71 in combination with ruxolitinib under the conditions of this study.
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   AAML1531 - Risk-stratified Therapy for Acute Myeloid Leukemia in Down...
        Protocol No.
        HSC20170204XT
        Official Title
        AAML1531 - Risk-stratified Therapy for Acute Myeloid Leukemia in Down Syndrome. A COG Groupwide Phase 3 Study (CTMS# 17-0058)
        Description
        1.1 Primary Aims 1.1.1 To determine the 2-year event-free-survival (EFS) for children with standard risk DS AML (MRD-negative after one cycle of induction therapy) after elimination of HD Ara-C from the treatment regimen. 1.1.2 To determine the 2-year EFS for children with high risk DS AML (MRD-positive after one cycle of induction therapy) after intensification of treatment equivalent to that used for high risk AML in children without DS. 1.2 Exploratory Aims 1.2.1 To determine the extent to which elimination of HD Ara-C from the treatment of standard risk DS AML decreases adverse events and resource utilization. Specifically, to determine if elimination of HD Ara-C from treatment of standard risk DS AML results in: 1.2.1.1 A significant decrease in the number of days per patient spent on protocol therapy compared to predecessor study AAML0431. 1.2.1.2 A significant decrease in the average number of days of hospitalization per patient compared to predecessor studies AAML0431 and A2971. 1.2.1.3 A significant decrease in the number (per patient) and rate (per duration of treatment) of sterile site infections compared to the predecessor study AAML0431. 1.2.1.4 A significant decrease of resource utilization by AML treatment compared to the predecessor study AAML0431. 1.2.2 To compare the feasibility and analytical characteristics of flow cytometry, PCR and targeted error-corrected sequencing of GATA1 mutations as methods to detect MRD in DS AML. 1.2.3 To establish a DS AML cell bank of viably frozen bone marrow samples collected at the end of induction and corresponding non-tumor DNA samples collected at end of Induction 1.
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

    •   Non-Hodgkin Lymphoma

      •   A Randomized Phase II Trial of Brentuximab Vedotin (SGN35, NSC# 749710), or...
        Protocol No.
        HSC20160299XT
        Official Title
        A Randomized Phase II Trial of Brentuximab Vedotin (SGN35, NSC# 749710), or Crizotinib (NSC#749005, commercially labeled) in Combination with Chemotherapy for Newly Diagnosed Patients with Anaplastic Large Cell Lymphoma (ALCL) IND # 117117 (CTMS 16-0059)
        Description
        1.1 Primary Aims 1.1.1 Tolerability - To determine the tolerability of brentuximab vedotin given in combination with standard chemotherapy (ALCL99) and to determine the tolerability of crizotinib given in combination with chemotherapy (ALCL99). 1.1.2 Event Free Survival -To estimate the Event Free Survival (EFS) of Arm BV and Arm CZ and contrast these to historical control data. 1.2 Secondary Aim 1.2.1 MDD/MRD - To determine the prognostic significance of minimal disseminated disease (MDD) at diagnosis and minimal residual disease (MRD) as measured by RT- polymerase chain reaction (PCR) in peripheral blood.
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   Phase Ib clinical trial of roflumilast added to standard chemoimmunotherapy...
        Protocol No.
        HSC20180073HU
        Official Title
        Phase Ib clinical trial of roflumilast added to standard chemoimmunotherapy for high-risk diffuse large B-cell lymphoma (CTMS# 17-0087)
        Description
        To determine the safety and tolerability of oral roflumilast at a dose of 500 µg daily given concurrently with R-CHOP to patients with newly diagnosed DLBCL at moderate or high risk for poor outcomes, defined as an NCCN-IPI score of 2 or greater.
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

    •   Other Hematopoietic

      •   A Phase 2 Single-Arm, Open-Label Study Evaluating Tolerability and Efficacy...
        Protocol No.
        HSC20170719HU
        Official Title
        A Phase 2 Single-Arm, Open-Label Study Evaluating Tolerability and Efficacy of Navitoclax in Combination with Ruxolitinib in Subjects with Myelofibrosis (CTMS# 17-0117)
        Description
        The primary objective of the study is: To evaluate the effect of the addition of navitoclax to ruxolitinib on spleen volume The secondary objectives of the study are: To assess the effect of the addition of navitoclax to ruxolitinib on total symptom score (TSS) as assessed by the Myelofibrosis Symptom Assessment Form (MFSAF) version 4.0 diary To evaluate the effect of the addition of navitoclax to ruxolitinib on bone marrow fibrosis To determine the overall response rate (ORR = sum of rates of complete remission [CR] + partial remission [PR]) associated with the addition of navitoclax to ruxolitinib To determine the rate of anemia response associated with the addition of navitoclax to ruxolitinib To describe the safety profile and PK profile observed with the addition of navitoclax to ruxolitinib
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   An Open-label, Single Arm, Phase 2 Study to Evaluate Efficacy and Safety of...
        Protocol No.
        HSC20180672XT
        Official Title
        An Open-label, Single Arm, Phase 2 Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients with Advanced Systemic Mastocytosis (CTMS# 18-0071)
        Description
        The primary objective is to determine ORR (CR/CR with partial recovery of peripheral blood counts [CRh] + PR + CI) based on modified IWG-MRT-ECNM consensus response criteria in patients with AdvSM treated with avapritinib.
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   Prospective, Longitudinal, Non-Interventional Study of Disease Burden and...
        Protocol No.
        HSC20180342XT
        Official Title
        Prospective, Longitudinal, Non-Interventional Study of Disease Burden and Treatment of Patients with Low-Risk Myelofibrosis (MF) or High-Risk Essential Thrombocythemia (ET) or ET Patients Receiving ET-Directed Therapy (CTMS# 18-0005)
        Description
        Describe clinical characteristics and evolution of disease burden in the essential thrombocythemia (ET) and myelofibrosis (MF) cohorts per Protocol definitions.
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

    •   Ovary

      •   Use of the CA 125 Algorithm for the Early Detection of Ovarian Cancer in Low...
        Protocol No.
        HSC20170396HU
        Official Title
        Use of the CA 125 Algorithm for the Early Detection of Ovarian Cancer in Low Risk Women (CTMS# 17-0014)
        Description
        To evaluate the longitudinal CA-125 algorithm for the early detection of ovarian cancer in a low risk cohort of women.
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

    •   Pancreas

      •   A Phase 1b (Open-Label) / Phase 2 (Randomized, Double-Blinded) Study...
        Protocol No.
        HSC20180380XT
        Official Title
        A Phase 1b (Open-Label) / Phase 2 (Randomized, Double-Blinded) Study Evaluating Nab-Paclitaxel and Gemcitabine With or Without Olaratumab in the Treatment of First-Line Metastatic Pancreatic Cancer (CTMS# 18-0001)
        Description
        Phase 1b: to determine a recommended Phase 2 dose of olaratumab in combination with nab-paclitaxel and gemcitabine Phase 2: to compare the efficacy of olaratumab plus nab-paclitaxel and gemcitabine with placebo plus nabpaclitaxel and gemcitabine
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

    •   Prostate

      •   A Phase II, Double-Blinded, Placebo-Controlled Randomized Trial of Salvage...
        Protocol No.
        HSC20180809XT
        Official Title
        A Phase II, Double-Blinded, Placebo-Controlled Randomized Trial of Salvage Radiotherapy With or Without Enhanced Anti-Androgen Therapy with Apalutamide in Recurrent Prostate Cancer (CTMS# 18-0115)
        Description
        To determine whether, in men with post-prostatectomy PSA recurrences, salvage radiation (SRT) with enhanced anti-androgen therapy with apalutamide will improve biochemical progression-free survival (bPFS) compared to SRT alone. A bPFS event is defined as a rise in PSA > 0.2 ng/mL from nadir, confirmed by a second PSA measurement ; clinical or radiographic local, regional, or distant metastases; or death from any cause, whichever occurs first.
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   A Pivotal, Prospective, Three-Stage, Single-Arm Study of Focal Ablation of...
        Protocol No.
        HSC20180762XT
        Official Title
        A Pivotal, Prospective, Three-Stage, Single-Arm Study of Focal Ablation of the Prostate with NanoTherm Therapy¿ System for a Limited-Volume, Clinically Localized, Intermediate-Risk Prostate Cancer (CTMS# 18-0113)
        Description
        The primary objective of Stage 1 of this study is to demonstrate the effectiveness and accuracy of the NanoTherm Therapy System in ablation of prostate cancer lesions, histopathology-proven at 8 weeks (-2 weeks, + 4 weeks) post-treatment in this patient population of men electing prostatectomy.
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   A Two-Part Prospective Study to Measure the Impact of Adding Genomic Testing...
        Protocol No.
        HSC20160493HU
        Official Title
        A Two-Part Prospective Study to Measure the Impact of Adding Genomic Testing (Prolaris®) on the Treatment Decision Following Biopsy in Newly Diagnosed Prostate Cancer Patients with Long Term Follow-up Post-Treatment to Measure the Prediction of Progression/Recurrence in Men Treated in the Veterans Administration Medical Center (VAMC) P-PROVE - Prospective Prolaris® Value and Efficacy (CTMS 16-0132)
        Description
        The objectives of the study include: ¿ To estimate the impact of a biopsy based genomic risk assessment tool (Prolaris®) on the magnitude of change between the PRE-Prolaris® test selection of treatment option for clinically localized prostate cancer and the ACTUAL implemented treatment administered following the genomic test results.  To estimate the impact of a biopsy based genomic risk assessment tool (Prolaris®) on the magnitude of change between the PRE-Prolaris® test selection of treatment option for early-stage prostate cancer and the POSTProlaris ® test treatment plan following consultation with the patient.  To estimate the impact of a biopsy based genomic risk assessment tool (Prolaris®) on the magnitude of change between physician''s initial likelihood of recommending non-interventional therapy for early-stage prostate cancer and the likelihood following the genomic test results
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   An Interventional Study to Reduce Folate Levels in Men on Active...
        Protocol No.
        HSC20160340HU
        Official Title
        An Interventional Study to Reduce Folate Levels in Men on Active Surveillance for Prostate Cancer (CTMS# 16-0070)
        Description
        Ascertain the impact of a low folate (folic acid) enriched diet- a reverse dietary intervention- on prostate cancer prevention and progression.
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   Clinical Evaluation of the ExoDx Prostate (IntelliScore) in men presenting...
        Protocol No.
        HSC20170067HU
        Official Title
        Clinical Evaluation of the ExoDx Prostate (IntelliScore) in men presenting for initial biopsy: impact on decision-making and health economics (CTMS 16-0040)
        Description
        1.1. Primary Objective 1.1.1. Evaluate impact of the ExoIntelliScore Prostate on the decision to perform an initial prostate biopsy for men presenting with an elevated PSA (2-10 ng/mL). 1.2. Secondary and Exploratory Objectives 1.2.1. Assess physician satisfaction with the ExoIntelliScore Prostate report including test result presentation, graphics and interpretation. 1.2.2. Assess patient satisfaction for ease of understanding test results and role on decision process to have a biopsy. 1.2.3. Determine the medical economic impact of the ExoIntelliScore Prostate in the prostate biopsy decision process. 1.2.4. Correlation of the ExoIntelliScore Prostate score with the actual biopsy result. 1.2.5. The goal of this study is to evaluate how the urologist will utilize the ExoIntelliScore Prostate score in the decision process to perform an initial prostate needle biopsy for men presenting for an equivocal PSA.
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   EA8171, Multiparametric MRI (mpMRI) for Preoperative Staging and Treatment...
        Protocol No.
        HSC20180668XT
        Official Title
        EA8171, Multiparametric MRI (mpMRI) for Preoperative Staging and Treatment Planning for Newly-Diagnosed Prostate Cancer (CTMS# 18-0091)
        Description
        To estimate the diagnostic performance of overall PI-RADS score based on local site imaging review of mpMRI (T2W, DWI and DCE) to detect clinically significant prostate cancer. To develop a risk prediction model by incorporating overall PI-RADS, PSA, Gleason score and clinical stage to predict the presence of clinically significant prostate cancer.
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   Impact of a home-based exercise program on prognostic biomarkers in men with...
        Protocol No.
        HSC20160604HU
        Official Title
        Impact of a home-based exercise program on prognostic biomarkers in men with prostate cancer (CTMS 15-0008)
        Description
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   Improving the Detection of Prostate Cancer in Men with Low Serum PSA (CTMS...
        Protocol No.
        HSC20160310HU
        Official Title
        Improving the Detection of Prostate Cancer in Men with Low Serum PSA (CTMS 16-0055)
        Description
        Utilize biomarkers and imaging to identify men who have prostate cancer but low PSA levels.
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   Phase Ib Trial of Encapsulated Rapamycin (eRapa) in Prostate Cancer Patients...
        Protocol No.
        HSC20180371XT
        Official Title
        Phase Ib Trial of Encapsulated Rapamycin (eRapa) in Prostate Cancer Patients under Active Surveillance (CTMS# 18-0021)
        Description
        Safety: To evaluate the number, frequency, duration, and relation of toxicity events to eRapa, as defined by the Common Terminology Criteria for Adverse Events (CTCAE) v 4.03; analyzed overall and compared between dosing cohorts. Also assessed based on duration of treatment.
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   San Antonio Center of Biomarkers of Risk for Prostate Cancer (SABOR) (CTRC...
        Protocol No.
        HSC20000030H
        Official Title
        San Antonio Center of Biomarkers of Risk for Prostate Cancer (SABOR) (CTRC HSC20000030H)
        Description
        The San Antonio Center of Biomarkers of Risk for Prostate Cancer (SABOR), is a long-term research study of a large group of men that will help researchers improve the detection of prostate cancer.  The program provides annual PSA (Prostate Specific Antigen) screening at no cost.  Subjects participating in this study will be asked to attend one visit per year for PSA screening and complete annual follow-up phone interviews. Written PSA results will be provided to you, and if you request, to your provider
        Contact
        210-567-0178
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

    •   Soft Tissue

      •   A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide...
        Protocol No.
        HSC20160538XT
        Official Title
        A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating with Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864, IND# 122782) in Patients with Intermediate Risk (IR) Rhabdomyosarcoma (RMS) (CTMS 16-0116)
        Description
        Primary Aims: 1.1 To compare the event-free survival (EFS) of patients with IR RMS treated with surgery, radiotherapy, and VAC alternating with VI (VAC/VI) to that of patients treated with surgery, radiotherapy and VAC/VI plus temsirolimus (TORI). Secondary Aims: 1.2 To compare the overall survival (OS) of patients with IR RMS treated with surgery, radiotherapy, and VAC alternating with VI to that of patients treated with surgery, radiotherapy and VAC/VI plus TORI. Exploratory Aims: 1.3.1 To compare the outcome of patients based on their FOXO1 fusion gene partner, by evaluation PAX3 vs. PAX7 in all patients found to be FOXO1 fusion positive. 1.3.2 To compare the outcome of patients based on their [F18]-fluorodeoxy-D-glucose-positron emission tomography (FDG-PET) response at Week 9 (positive or negative), as assessed by Deauville Criteria (5-point).
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

    •   Stomach

    •   Urinary Bladder

      •   Multi-Institutional Study to Evaluate DNA Methylation Markers for Detection...
        Protocol No.
        HSC20160419HU
        Official Title
        Multi-Institutional Study to Evaluate DNA Methylation Markers for Detection of Primary Bladder Cancers in Urine Samples From a Cohort of Patients With Hematuria (CTMS 16-0094)
        Description
        The primary objective of this study is to evaluate the performance of the methylation marker panel for the detection of bladder cancer in patients with gross or microscopic hematuria. The secondary objective is to evaluate the predictive accuracy of a risk model including clinical factors such as age, gender, smoking history, and presence of gross versus microscopic hematuria compared to a model incorporating the same risk factors along with the methylation marker panel.
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   S1602, A Phase III Randomized Trial to Evaluate the Influence of BCG Strain...
        Protocol No.
        HSC20170087HU
        Official Title
        S1602, A Phase III Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming with Intradermal BCG Before Intravesical Therapy for BCG-Naive High-Grade Non-Muscle Invasive Bladder Cancer (CTMS# 16-0138)
        Description
        Primary Objectives To compare whether time to high-grade recurrence (TTHGR) for patients with BCG-naive, non-muscle invasive bladder cancer (NMIBC) receiving Tokyo-172 BCG strain (Arm 2) is non-inferior to patients receiving BCG LIVE (TICE® BCG) strain (Arm 1). To test whether TTHGR for patients with BCG-naive, NMIBC receiving intradermal Tokyo-172 BCG vaccination followed by intravesical Tokyo-172 BCG instillation (Arm 3) is superior to patients receiving intravesical Tokyo-172 BCG instillation without prior intradermal BCG vaccination (Arm 2). Secondary Objectives To compare time to recurrence (TTR) with any-grade (AG) bladder cancer between: 1. Patients receiving Tokyo-172 versus BCG LIVE (TICE® BCG) strain, 2. Patients receiving intradermal + intravesical versus intravesical only Tokyo-172 BCG. To compare progression-free survival (PFS) between: 1. Patients receiving Tokyo-172 versus BCG LIVE (TICE® BCG) strain, 2. Patients receiving intradermal + intravesical versus intravesical only Tokyo-172 BCG. c. To compare 6-month complete response in patients with Carcinoma in situ (CIS) present at baseline with or without Ta or T1 cancer receiving: 1. Tokyo-172 versus BCG LIVE (TICE® BCG) strain, 2. Intradermal + intravesical versus intravesical only Tokyo-172 BCG.
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

      •   S1605, Phase II Trial of Atezolizumab in BCG-Unresponsive Non-Muscle...
        Protocol No.
        HSC20180230XT
        Official Title
        S1605, Phase II Trial of Atezolizumab in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer (CTMS# 18-0014)
        Description
        To estimate complete response at 25 weeks after registration for those with a CIS component and to evaluate event-free survival at 18 months in patients with BCG-unresponsive high-risk non-muscle invasive bladder cancer (Ta/T1/CIS) treated with atezolizumab.
        Locations
        UT Health Science Center
        CTRC Clinical Trials Website
        View all Cancer Therapy & Research Center clinical trials
        Learn More About This Study

         

  •   Children's Health

    •   A study of carfilzomib in combination with cyclophosphamide and etoposide...
      Protocol No.
      HSC20160206H
      Official Title
      Phase I study of carfilzomib in combination with cyclophosphamide and etoposide for children with relapsed and refractory solid tumors and leukemias
      Description
      To evaluate the highest dose of carfilzomib that can be given safely together with cyclophosphamide and etoposide for children with solid tumor or leukemia that is not yielding to standard treatment and or is worsening.
      Contact
      210-562-9025
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Genomics of immune mediated diseases
      Protocol No.
      HSC20160018H
      Official Title
      Genomics of Immune Mediated Diseases
      Description
      New diseases of the immune system can be discovered by studying the genetic makeup of patients with a strong family history. In addition to providing a diagnosis, genetic studies can suggest better treatments in some cases. We are looking for children with immune mediated symptoms, including immune deficiency, inflammatory symptoms such as fever, and episodes of swelling, with at least one close relative (parent or sibling) who has the same symptom(s) and another who is not affected. Blood samples will be taken and analyzed for genetic differences.
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   GO29665, A PHASE I/II, MULTICENTER, OPEN-LABEL, DOSE-ESCALATION STUDY OF THE...
      Protocol No.
      HSC20160080H
      Official Title
      GO29665, A PHASE I/II, MULTICENTER, OPEN-LABEL, DOSE-ESCALATION STUDY OF THE SAFETY AND PHARMACOKINETICS OF COBIMETINIB IN PEDIATRIC AND YOUNG ADULT PATIENTS WITH PREVIOUSLY TREATED SOLID TUMORS (CTRC# 15-0005)
      Description
      CTRC# 15-0005
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Health4Kids Intervention Trial for Hispanic Families
      Protocol No.
      HSC20130465H
      Official Title
      Health4Kids (H4K) Intervention Trial for Hispanic Families
      Description
      Health4Kids is an obesity management study that uses family counseling, text messages and newsletters to encourage healthy eating and physical activity. This study enrolls 6-11 year-old, obese/overweight Latino children (and a parent) who are existing patients at University Health System pediatric clinics in San Antonio.
      Contact
      210-562-6514
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Improvements in Brain Function during Psychotherapy For Teens with Symptoms...
      Protocol No.
      HSC20160637H
      Official Title
      Improvements in Brain Function during Psychotherapy For Teens with Posttraumatic Stress
      Description
      The purpose of the study is to analyze how brain functioning improves when symptoms of posttraumatic stress improve during psychotherapy. Teens who have experienced trauma and are bothered by symptoms of stress will be provided with the ‘gold-standard’ psychotherapy for trauma, at no-cost. They will have brain scans using Magnetic Resonance Imaging (MRI) before, during, and after the treatment: a total of 4 brain scans over the 20-week treatment. MRI is safe and does not use radiation or injections.
      Contact
      210-567-8162
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Placebo-Controlled Efficacy and Safety Study of Ataluren in Patients with...
      Protocol No.
      HSC20170289H
      Official Title
      A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED EFFICACY AND SAFETY STUDY OF ATALUREN IN PATIENTS WITH NONSENSE MUTATION DUCHENNE MUSCULAR DYSTROPHY AND OPEN-LABEL EXTENSION
      Description
      The main goals of this study are to obtain additional information on whether the actions of ataluren can slow disease progression
      Contact
      210-567-8222
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   POE16-01, A study of neratinib in children and adolescent and young adults...
      Protocol No.
      HSC20170390H
      Official Title
      POE16-01, A Phase I/II Study of Neratinib in Pediatric Patients with Relapsed/Refractory Solid Tumors or Hematologic Malignancies
      Description
      To evaluate the highest dose of neratinib that can be given safely for children with solid tumor or leukemia that is not yielding to standard treatment and or is worsening.
      Contact
      210-743-2332
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   The Chromosome 18 Clinical Research Center.
      Protocol No.
      HSC20000318H
      Official Title
      The Chromosome 18 Clinical Research Center.
      Description
      To learn as much as possible about the medical and educational effects of a chromosome 18 deletion or duplication, and to learn about the genes that are duplicated or deleted.
      Contact
      210-567-5321
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   The Impact of Prenatal Opioid Use on Maternal-Infant Dyad
      Protocol No.
      HSC20180057H
      Official Title
      The Impact of Prenatal Opioid Use on Maternal-Infant Dyad
      Description
      Opioid exposure during pregnancy may place babies at risk for developing neonatal abstinence syndrome. The purpose of this study is to explore the impact of prenatal opioid use on stress and physiological attunement in mother-baby dyads. We are recruiting opioid and non-opioid using pregnant women.
      Contact
      210-450-8294
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Tooth Fairy Study
      Protocol No.
      HSC20110313H
      Official Title
      Potential Risk Factors Associated with Autism Spectrum Disorders
      Description
      Participate in the Tooth Fairy Study! Our research team recently discovered that toxins such as plastics, pesticides and medications are stored in baby teeth as they are forming during pregnancy and shortly thereafter. The cause of autism is unknown; however, genetic and environmental factors are both likely involved. This study is being done to learn if children with autism have been exposed to more environmental toxins than typically-developing children and to learn if their genes are more vulnerable to the toxins. We are currently enrolling biological mothers of children with autism, their siblings AND mothers of children developing normally. Participants will fill out a survey regarding nutrition and exposures (~30 minutes), and donate their child’s baby teeth. To be eligible for this study… • You must be the biological mother of a child who is 2 years or older. • Your child must either have an established or suspected diagnosis of autism OR be a typically-developing child with no chronic medical problems • You must have a tooth from your child in good condition (not too worn or large cavities/crowns) To learn more about this study… Contact Lynne Heilbrun, MPH at heilbrun@UTHSCSA.edu.
      Contact
      210-274-4009
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Understanding the genetics of bipolar I disorder in adolescents
      Protocol No.
      HSC20150334H
      Official Title
      Application of induced pluripotent stem cells for the study of bipolar I disorder
      Description
      The purpose of this research is to develop a cell-based system to study adolescent bipolar I disorder to better understand genetic and epigenetic mechanisms associated with risk and develop new methods for treatment. We will perform MRI, neurocognitive and neuropsychiatric testing and draw blood.
      Contact
      210-258-9766
      Locations
      UT Health Science Center
      Learn More About This Study

       

  •   Diabetes

    •   Can the following Diabetes Medications: GLP-1 Receptor Agonist, Exenatide,...
      Protocol No.
      HSC20170582H
      Official Title
      SGLT2 INHIBITION AND STIMULATION OF ENDOGENOUS GLUCOSE PRODUCTION Significance : Protocol- 4 Can the GLP-1 Receptor Agonist, Exenatide, Prevent the Increase in EGP in Response to Dapagliflozin-induced Increase in Glucosuria
      Description
      We are working on a research study that examines diabetes and the role of increased plasma glucagon, decline in plasma insulin, and fall in plasma glucose concentration. We will examine the difference in Endogenous Glucose Production between the drug-treatment (Dapagliflozin) and Placebo-treatment groups.
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Colesevelam Oral Suspension as Monotherapy or Add on to Metformin Therapy in...
      Protocol No.
      HSC20110050H
      Official Title
      Colesevelam Oral Suspension as Monotherapy or Add on to Metformin Therapy in Pediatric Subjects with Type 2 Diabetes Mellitus Protocol WEL-A-U307
      Description
      The primary objective of the study is to demonstrate the effects of covesevelam HCI oral suspension as monotherapy or as an addon therapy to metformin on change in HbA1c from baseline over the first 6-month treatment period in pediatric subjects with type 2 diabetes mellitus.
      Contact
      210-704-4443
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Durability of Early Combination Therapy vs Conventional Therapy in New Onset...
      Protocol No.
      HSC20080456H
      Official Title
      Durability of Early Combination Therapy vs Conventional Therapy in New Onset Diabetes
      Description
      This research study is exploring the way we currently prescribe medications to treat type 2 DM. Step-therapy (Conventional Therapy) with metformin, then a sulfonylurea, then basal insulin, as needed to optimize glycemic control is being compared to therapy with three medications from enrollment (Early Combination). These medications include metformin, pioglitazone, and exenatide.
      Contact
      210-358-7200
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Effect of GLP-1 Receptor Agonist, Exenatide on Glucosuria Induced Elevation...
      Protocol No.
      HSC20160597H
      Official Title
      Effect of Chronic Exenatide Therapy on Beta Cell Function and Insulin Sensitivity in T2DM
      Description
      Examine diabetes and the role of increased plasma glucagon, decline in plasma insulin, and fall in plasma glucose concentration. Hope to learn about SGLT2 inhibition on EGP (endogenous glucose production) and plasma glucose concentration in diabetic subjects.
      Contact
      567-6710
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   EFFECT OF DIABETIC MEDICINES ( FARXIGA AND METFORMIN) ON RENAL FUNCTION AND...
      Protocol No.
      HSC20160262H
      Official Title
      EFFECT OF FARXIGA ON RENAL FUNCTION AND SIZE IN TYPE 2 DIABETIC PATIENTS WITH HYPERFILTRATION
      Description
      We propose to treat newly diagnosed T2DM patients with Farxiga or metformin for 4 months. Inclusion Criteria: (i) age = 30-70 years; (ii) BMI = 20-45 kg/m2; (iii) A1c = 7.5% to 12%; (iv) male or female; (v) willingness to participate in the 16 week study protocol
      Contact
      210-358-7200
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Effect of the Diabetes Medication - Dapagiflozin on glucose use by the liver
      Protocol No.
      HSC20170214H
      Official Title
      Effect of Empagliflozin on hepatic glucose metabolism: role of autonomic nervous system
      Description
      Dapagliflozin is a novel unique drug recently approved by the FDA for the treatment of type 2 diabetes. In previous studies, we found that in addition to lowering glucose sugar levels in the blood, dapagliflozin increases glucose sugar production by the liver and increases the rate of fat oxidationburning fat in the body. These actions of the drug decrease its effectivnessefficacy in lowering the blood sugar and increase the risk of complications. The aim of of the presentthis study is to understand the mechanism way by whichthat dapagliflozin causes the liver to increase sugar production and fat burning so that these actions, this allows us we can tothen develop methods to prevent them. You are being asked to be a participant in this study because you have type 2 diabetes and your blood sugar is not too high that requires treatment with medications. Or you do not have diabetes and the results of your tests will be used to compare to those with diabetes.
      Contact
      210-567-6710
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Evaluate the Safety and Effectiveness of Duodenal Mucosal Resurfacing (DMR)...
      Protocol No.
      HSC20180546H
      Official Title
      Randomized, Double-Blind, Sham-Controlled, Prospective, Multi-Center Pilot Study to Evaluate the Safety and Effectiveness of Duodenal Mucosal Resurfacing Using the Revita System in the Treatment of Type 2 Diabetes
      Description
      The study device, the Fractyl Revita System, is being tested for the treatment of Type 2 diabetes. The purpose of this study is to learn more about the use of the Revita System for the treatment of Type 2 diabetes. The Revita System is experimental (not FDA approved) for the treatment of Type 2 Diabetes.
      Contact
      210-358-7200
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Paradoxical Stimulation of Hepatic Glucose Production with Dapagliflozin (P2)
      Protocol No.
      HSC20160586H
      Official Title
      Paradoxical Stimulation of Hepatic Glucose Production with Dapagliflozin (P2)
      Description
      The present study will provide novel insights concerning the regulation of glucose homeostasis and has direct and important clinical implications. We will determine the role of pancreatic hormones (increase in plasma glucagon and decrease in plasma insulin concentration) in the stimulation of EGP (Endogenous Glucose Production) following SGLT2 inhibition.
      Contact
      210-567-6691
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Preservation of Beta Cell Function in pre-diabetes in subject with impaired...
      Protocol No.
      HSC20130414H
      Official Title
      Preservation of Beta Cell Function in pre-diabetes in subject with impaired fasting glucose (IFG) and impaired glucose tolerance (IGT)
      Description
      This study will identify individuals who may have early signs of developing diabetes and understand how early treatment will help their body in controlling blood sugar levels and protecting function of their pancreas.
      Contact
      210-358-7200
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   The Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness...
      Protocol No.
      HSC20130205H
      Official Title
      The Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE Study)
      Description
      IF YOU ARE: Have diabetes for less than 5 years but otherwise healthy and Taking Metformin as your only diabetes medication, you may be eligible to join a clinical trial conducted by the Diabetes Division of the UTHSCSA at the Texas Diabetes Institute (TDI).
      Contact
      210-358-7200
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Understanding the Cardiovascular Benefits of the Anti-Diabetes Medication...
      Protocol No.
      HSC20180077H
      Official Title
      SGLT2 INHIBITORS, KETONES, & CARDIOVASCULAR BENEFIT CTMS 18-0009
      Description
      A recently published study (The EMPA-REG OUTCOME trial) showed that the antidiabetic medication empagliflozin reduced cardiovascular mortality and hospitalization for heart failure, resulting in the drug’s approval by the FDA for the treatment of type 2 diabetic patients with cardiovascular disease. However, the reasons why the medication achieved these benefits remains unknown. In diabetic patients, this medication has shown to increase ketone (the breakdown of fat) levels in blood. In this study, we will try to mimic this increase of fat break down and assess heart function with MRI and PET imaging technology.
      Contact
      210-358-7200
      Locations
      UT Health Science Center
      Learn More About This Study

       

  •   Diagnostic

    •   Assessing Brain Injury Following Drowning Using Resting-state Functional...
      Protocol No.
      HSC20120268H
      Official Title
      Assessing Brain Injury Following Drowning Using Resting-state Functional Magnetic Resonance Imaging
      Description
      In a population of pediatric HIE due to nonfatal drowning, we hypothesize that neural system integrity as determined by functional brain imaging will be highly predictive of patients’ functional status as determined by quantitative clinical examination. This hypothesis will be tested using independent components analysis (ICA) of resting-state functional magnetic resonance imaging (fMRI) in a population of pediatric hypoxic-ischemic encephalophy (HIE) secondary to nonfatal drowning.
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Genomics of immune mediated diseases
      Protocol No.
      HSC20160018H
      Official Title
      Genomics of Immune Mediated Diseases
      Description
      New diseases of the immune system can be discovered by studying the genetic makeup of patients with a strong family history. In addition to providing a diagnosis, genetic studies can suggest better treatments in some cases. We are looking for children with immune mediated symptoms, including immune deficiency, inflammatory symptoms such as fever, and episodes of swelling, with at least one close relative (parent or sibling) who has the same symptom(s) and another who is not affected. Blood samples will be taken and analyzed for genetic differences.
      Locations
      UT Health Science Center
      Learn More About This Study

       

  •   Ear, Nose and Throat

    •   Hereditary causes of atretic ear canals (absense of an ear canal)
      Protocol No.
      HSC20040104H
      Official Title
      Molecular Characterization of Individuals with Ear Canal Atresia
      Description
      The researchers hope to learn more about the causes of atretic ear canals (absence of an ear canal). We will be looking for abnormalities in the hereditary material (DNA) which could cause atretic ear canals. We hope our results will help people with this disorder in the future.
      Locations
      UT Health Science Center
      Learn More About This Study

       

  •   Family Health

    •   Metformin and vaccine response in older adults
      Protocol No.
      HSC20180171H
      Official Title
      Metformin and vaccine response in older adults
      Description
      Older adults’ immune systems will weaken with age. Over time, it becomes more difficult to mount an adequate immune response to vaccines to protect against subsequent infections, such as pneumonia. This study will provide information on whether a treatment with metformin will improve ‘pneumonia’ vaccine responses in older adults. Participants will be followed for 3 months.
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   The Impact of Prenatal Opioid Use on Maternal-Infant Dyad
      Protocol No.
      HSC20180057H
      Official Title
      The Impact of Prenatal Opioid Use on Maternal-Infant Dyad
      Description
      Opioid exposure during pregnancy may place babies at risk for developing neonatal abstinence syndrome. The purpose of this study is to explore the impact of prenatal opioid use on stress and physiological attunement in mother-baby dyads. We are recruiting opioid and non-opioid using pregnant women.
      Contact
      210-450-8294
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Tooth Fairy Study
      Protocol No.
      HSC20110313H
      Official Title
      Potential Risk Factors Associated with Autism Spectrum Disorders
      Description
      Participate in the Tooth Fairy Study! Our research team recently discovered that toxins such as plastics, pesticides and medications are stored in baby teeth as they are forming during pregnancy and shortly thereafter. The cause of autism is unknown; however, genetic and environmental factors are both likely involved. This study is being done to learn if children with autism have been exposed to more environmental toxins than typically-developing children and to learn if their genes are more vulnerable to the toxins. We are currently enrolling biological mothers of children with autism, their siblings AND mothers of children developing normally. Participants will fill out a survey regarding nutrition and exposures (~30 minutes), and donate their child’s baby teeth. To be eligible for this study… • You must be the biological mother of a child who is 2 years or older. • Your child must either have an established or suspected diagnosis of autism OR be a typically-developing child with no chronic medical problems • You must have a tooth from your child in good condition (not too worn or large cavities/crowns) To learn more about this study… Contact Lynne Heilbrun, MPH at heilbrun@UTHSCSA.edu.
      Contact
      210-274-4009
      Locations
      UT Health Science Center
      Learn More About This Study

       

  •   Genetics

    •   The Chromosome 18 Clinical Research Center.
      Protocol No.
      HSC20000318H
      Official Title
      The Chromosome 18 Clinical Research Center.
      Description
      To learn as much as possible about the medical and educational effects of a chromosome 18 deletion or duplication, and to learn about the genes that are duplicated or deleted.
      Contact
      210-567-5321
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Understanding Type and Quality of Relationships between Individuals with...
      Protocol No.
      HSC20070194H
      Official Title
      Understanding Type and Quality of Relationships between Individuals with Chromosome 18 Abnormalities and their Siblings
      Description
      Relationships between Individuals with Chromosome 18 Abnormalities and their Siblings
      Contact
      210-567-5321
      Locations
      UT Health Science Center
      Learn More About This Study

       

  •   Healthy Subjects Needed

    •   Bariatric Surgeries and Glucose Metabolism
      Protocol No.
      HSC20180070H
      Official Title
      Bariatric Surgeries and Glucose Metabolism
      Description
      This research study is being performed to answer specific questions about changes in glucose metabolism after weight-loss surgery. Insulin is the main hormone that controls the level of glucose (sugar) in your blood. Two most commonly performed weight-loss surgeries (bariatric surgery), gastric bypass surgery and sleeve gastrectomy, improve glucose control in patients with type 2 diabetes before any weight loss happens. The amount of insulin that your body makes after eating is increased after these surgeries. Evidence suggests that these surgeries increase gut hormones, which in turn can increase insulin levels. One of the gut hormones is called GLP-1 or “glucagon-like peptide 1”. Another is called GIP or “glucose-dependent insulinotropic peptide”. This study will determine the effects of bariatric surgery on blood glucose levels and insulin response that are mediated by gut hormones as well as neural activity. You may qualify to take part in this research study if you are between 18 and 80 years of age and you either had weight loss surgery or because you are serving as a healthy volunteer who did not have any gut surgery (control subject).
      Contact
      210-450-8696
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Brain Network Validation Study
      Protocol No.
      HSC20170718H
      Official Title
      Brain Network Study: DLPFC Validation
      Description
      This study will provide important information about brain organization in healthy subjects, and can optimize a treatment for Major Depressive Disorder. We will be using Transcranial Magnetic Stimulation (aka TMS), a safe, non-invasive method for firing neurons on the surface of the brain. First, we will perform a magnetic resonance image (MRI) of the brain to plan a “personalized” TMS treatment. During a second visit we will use Positron Emission Tomography (PET), alongside TMS, to stimulate and measure activations and connections in the brain.
      Contact
      210-567-8049
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Brain Oxygen Utilization: Methods Validation
      Protocol No.
      HSC20170187H
      Official Title
      Brain Oxygen Utilization: Methods Validation
      Description
      This study is being done to test a new method for measuring brain oxygen use (oxygen metabolism) that will be faster, cheaper and more widely available than the older method. The new method uses MRI (Magnetic resonance imaging) that developed by a research group in Johns Hopkins University. The older method uses PET (positron emission tomography), which has been recognized as the gold standard for over 30 years. This study will compare the two methods in healthy, normal people, to test whether they give the same values.
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Canary Prostate Active Surveillance Study (PASS)
      Protocol No.
      HSC20080303H
      Official Title
      Canary Prostate Active Surveillance Study (PASS)
      Description
      All care participants receive is Standard of Care for Active Surveillance. Research procedures include blood draw every 6 months for serum and plasma, urine collections, prostate tissue collection, Food & Supplement Use Questionnaire and the Health-Related Quality of Life Questionnaire. Purpose of the PASS is to understand how prostate cancer behaves and to find unique biomarkers (substances in blood, urine or tissue which can indicate the presence of cancer) associated with prostate cancer. Eligibility Criteria: Participant must have clinically localized prostate cancer that has not been treated. Participant has elected active surveillance and decided not to undergo surgery, radiation, or other medical treatment for prostate cancer at this time.
      Contact
      210-450-0705
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Class switching, somatic hypermutation and plasma cell differentiation in B...
      Protocol No.
      HSC20140234H
      Official Title
      Class switching, somatic hypermutation and plasma cell differentiation in B cells. [Title of overall grant: Healthy Volunteer Blood Donor Program]
      Description
      This research study will investigate how certain immune cells make antibodies. Blood donors needed to act as normal, healthy controls for lupus research study.
      Contact
      210-567-3956
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Donation of Blood for Pilot Research Studies
      Protocol No.
      HSC20010081H
      Official Title
      Donation of Blood for Pilot Research Studies
      Description
      Research study of biochemical functions in blood cells, serum, and plasma. We want to learn about the normal function of platelets and the biochemical functions of enzymes in blood.
      Contact
      210-567-5532
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Effect of a pancreas produced hormone (Glucagon) on adipose (fat) tissue.
      Protocol No.
      HSC20170682H
      Official Title
      EFFECT OF PHYSIOLOGIC HYPERGLUCAGONEMIA ON ADIPOCYTE METABOLISM
      Description
      You are asked to participate in this research study to investigate the effect of high levels of glucagon- a hormone produced by the pancreas, on insulin action, particularly in adipose (fat) tissue. Very little information is available concerning the effect of high levels of glucagon on insulin action, particularly on peripheral tissues, including fat tissue. The researchers hope to learn the cause of disease andmechanisms of metabolic interruption that is induced by high levels of glucagon in type 2 diabetes patients.
      Contact
      210-567-4686
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Effect of mTOR Inhibition and other Metabolism Modulating Interventions on...
      Protocol No.
      HSC20120304H
      Official Title
      Effect of mTOR Inhibition and other Metabolism Modulating Interventions on the Elderly: Immune, Cognitive, and Fuctional Consequences.
      Description
      A research study of the mechanisms that are affected by the mTOR inhibition by Rapamycin. Rapamycin is a drug approved by the US Food and Drug Administration (FDA) for human use that has shown to increase lifespan in laboratory animals. In human medicine, Rapamycin is used is an immunosuppressant drug used to prevent rejection in organ transplantation; it is especially useful in kidney transplants. mTOR controls growth of cells in your body. Rapamycin reduced mTOR effects. The researchers hope to learn how mTOR inhibition affects humans by looking at how the immune system that is altered in normal aging and mTOR inhibition by Rapamycin. The information gained from these experiments will aid in understanding how mTOR inhibition works in humans and will provide new and important information on changes in age-related immune system regulation.
      Contact
      210-497-7279
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Effect of the Diabetes Medication - Dapagiflozin on glucose use by the liver
      Protocol No.
      HSC20170214H
      Official Title
      Effect of Empagliflozin on hepatic glucose metabolism: role of autonomic nervous system
      Description
      Dapagliflozin is a novel unique drug recently approved by the FDA for the treatment of type 2 diabetes. In previous studies, we found that in addition to lowering glucose sugar levels in the blood, dapagliflozin increases glucose sugar production by the liver and increases the rate of fat oxidationburning fat in the body. These actions of the drug decrease its effectivnessefficacy in lowering the blood sugar and increase the risk of complications. The aim of of the presentthis study is to understand the mechanism way by whichthat dapagliflozin causes the liver to increase sugar production and fat burning so that these actions, this allows us we can tothen develop methods to prevent them. You are being asked to be a participant in this study because you have type 2 diabetes and your blood sugar is not too high that requires treatment with medications. Or you do not have diabetes and the results of your tests will be used to compare to those with diabetes.
      Contact
      210-567-6710
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Human Innate Immunity and Tuberculosis
      Protocol No.
      HSC20170315H
      Official Title
      Human Innate Immunity and Tuberculosis
      Description
      Tuberculosis is an infection that primarily affects the lungs and causes fever and weight loss. While some people exposed to the tuberculosis (TB) bacteria develop the disease others do not. An important step in our understanding of these different responses is to measure the response of immune cells to infection with the TB bacteria. This study will request blood to be collected from healthy individuals and individuals who have had a positive test result for TB.
      Contact
      (210) 258-9577
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Immune Tests in Blood to Study Estrogens and Immune Co-Signal Effects on...
      Protocol No.
      HSC20110472H
      Official Title
      Immune Tests in Blood to Study Estrogens and Immune Co-Signal Effects on Immune Function in Age
      Description
      This study will help understand why immunity differs between men and women and how differences change over time. These data will help understand why women are more prone to autoimmunity, and how to use immune therapy effectively in different age groups and sexes. We will also test specific immune defects seen in mouse models of autoimmunity and cancer to determine if these defects also occur in humans.
      Contact
      450-1439
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Impact of disease associated noncoding polymorphisms on post-transcriptional...
      Protocol No.
      HSC20160074H
      Official Title
      Impact of Disease Associated Noncoding Polymorphisms on Post-Transcriptional Gene Regulation
      Description
      The purpose of this study is to identify genes and related RNA (ribonucleic acid) from healthy individuals, aged 18 to 35 years, that are expressed in our immune cells (i.e. the cells that fight infections in our body) that may be contributing to the risk of developing certain diseases like Crohn’s disease, atherosclerosis, and autoimmune diseases. This will be carried out by having study participants attend a short clinic visit that consists of a blood draw, a brief medical survey, and height/weight/blood pressure measurements.
      Contact
      210-601-6430
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Inflammatory cytokine response to 12-week anaerobic and aerobic exercise: a...
      Protocol No.
      HSC20180166H
      Official Title
      Inflammatory cytokine response to 12-week anaerobic and aerobic exercise: a comparative study.
      Description
      Our purpose is to determine the effects 12-week anaerobic and aerobic trainings have on inflammatory cytokines. Our objective is to enroll 20 healthy men into a 12-week anaerobic or aerobic training protocol.
      Contact
      210-606-2437
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Inflammatory cytokine response to an acute bout of aerobic and anaerobic...
      Protocol No.
      HSC20180165H
      Official Title
      Inflammatory cytokine response to acute anaerobic and aerobic exercise: a comparative study
      Description
      Our purpose is to determine the effects acute bouts of anaerobic and aerobic trainings have on inflammatory cytokines. Our objective is to enroll 20 healthy men into an anaerobic or aerobic exercise bout.
      Contact
      210-606-2437
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Metformin and vaccine response in older adults
      Protocol No.
      HSC20180171H
      Official Title
      Metformin and vaccine response in older adults
      Description
      Older adults’ immune systems will weaken with age. Over time, it becomes more difficult to mount an adequate immune response to vaccines to protect against subsequent infections, such as pneumonia. This study will provide information on whether a treatment with metformin will improve ‘pneumonia’ vaccine responses in older adults. Participants will be followed for 3 months.
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Mobile mindfulness training app for chronic pain patients
      Protocol No.
      HSC20180621H
      Official Title
      Evaluating a Mobile Mindfulness Training among Chronic Pain Patients Using Prescription Opioid CTMS#: CTMS 18-0117
      Description
      The purpose of this project is to explore the usefulness of a mobile mindfulness training, alongside standard of care, for individuals with chronic back and neck pain, in a four-week long study.
      Contact
      210-562-4682
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Pilot: Development and Optimization of MRI
      Protocol No.
      HSC20110120H
      Official Title
      Pilot: Development and Optimization of MRI
      Description
      The purpose of this study is to enable the development and optimization of non-invasive MRI pulse sequences, data acquisition and stimulation paradigms to be performed on members of the investigating team and in some occasions some external volunteers.
      Contact
      210-567-8181
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Prescription Opioid Research Study
      Protocol No.
      HSC20170141H
      Official Title
      Reducing the Abuse Liability of Prescription Opioids
      Description
      This is a study of new drug combinations to reduce the abuse potential of opioid analgesics. At the UT Pain Clinic the effect of these drug combinations on induced pain will be studied. Questions will be asked about how the drug affected you and whether you liked it.
      Contact
      210-562-4680
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Preservation of Beta Cell Function in pre-diabetes in subject with impaired...
      Protocol No.
      HSC20130414H
      Official Title
      Preservation of Beta Cell Function in pre-diabetes in subject with impaired fasting glucose (IFG) and impaired glucose tolerance (IGT)
      Description
      This study will identify individuals who may have early signs of developing diabetes and understand how early treatment will help their body in controlling blood sugar levels and protecting function of their pancreas.
      Contact
      210-358-7200
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Role of Lung Cells and Fluid in Tuberculosis
      Protocol No.
      HSC20170667H
      Official Title
      Human Alveolar Macrophages and Tuberculosis
      Description
      This work will increase understanding of M. tuberculosis interaction with human immune cells and/or lung fluid to aid in design of diagnostics and therapeutics. Human immune cells will be isolated from the blood and/or lung fluid, volunteers will not be exposed to M. tuberculosis.
      Contact
      210-258-9236
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Supporting Military Families with Young Children throughout the Deployment...
      Protocol No.
      HSC20150605H
      Official Title
      Supporting Military Families with Young Children throughout the Deployment Lifecycle: A Randomized Controlled Trial of Strong Families Strong Forces
      Description
      This research study will compare two ways of providing support to families with very young children when the family is going through a military deployment. The researchers hope to learn about the needs and challenges in parenting faced by Active Duty parents and spouses/partners who are coping with military-related separation and reintegration. Eligible participants are active duty military personnel and their spouse/partner who are stationed at Fort Hood, Texas; have at least one child 5 years or younger; spouse/partner will deploy within the next six months; and the deployment is expected to last at least three months.
      Contact
      254-288-1638
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   The Impact of Prenatal Opioid Use on Maternal-Infant Dyad
      Protocol No.
      HSC20180057H
      Official Title
      The Impact of Prenatal Opioid Use on Maternal-Infant Dyad
      Description
      Opioid exposure during pregnancy may place babies at risk for developing neonatal abstinence syndrome. The purpose of this study is to explore the impact of prenatal opioid use on stress and physiological attunement in mother-baby dyads. We are recruiting opioid and non-opioid using pregnant women.
      Contact
      210-450-8294
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Tooth Fairy Study
      Protocol No.
      HSC20110313H
      Official Title
      Potential Risk Factors Associated with Autism Spectrum Disorders
      Description
      Participate in the Tooth Fairy Study! Our research team recently discovered that toxins such as plastics, pesticides and medications are stored in baby teeth as they are forming during pregnancy and shortly thereafter. The cause of autism is unknown; however, genetic and environmental factors are both likely involved. This study is being done to learn if children with autism have been exposed to more environmental toxins than typically-developing children and to learn if their genes are more vulnerable to the toxins. We are currently enrolling biological mothers of children with autism, their siblings AND mothers of children developing normally. Participants will fill out a survey regarding nutrition and exposures (~30 minutes), and donate their child’s baby teeth. To be eligible for this study… • You must be the biological mother of a child who is 2 years or older. • Your child must either have an established or suspected diagnosis of autism OR be a typically-developing child with no chronic medical problems • You must have a tooth from your child in good condition (not too worn or large cavities/crowns) To learn more about this study… Contact Lynne Heilbrun, MPH at heilbrun@UTHSCSA.edu.
      Contact
      210-274-4009
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Understanding the genetics of bipolar I disorder in adolescents
      Protocol No.
      HSC20150334H
      Official Title
      Application of induced pluripotent stem cells for the study of bipolar I disorder
      Description
      The purpose of this research is to develop a cell-based system to study adolescent bipolar I disorder to better understand genetic and epigenetic mechanisms associated with risk and develop new methods for treatment. We will perform MRI, neurocognitive and neuropsychiatric testing and draw blood.
      Contact
      210-258-9766
      Locations
      UT Health Science Center
      Learn More About This Study

       

  •   Heart, Vascular and Blood

    •   Alternative Method for the Minimally Invasive Treatment of Persistent Atrial...
      Protocol No.
      HSC20160269H
      Official Title
      Amaze Trial: Left Atrial Appendage Ligation with the Lariat® Suture Delivery System as Adjunctive Therapy to Pulmonary Vein Isolation (PVI) for Persistent or Longstanding Persistent Atrial Fibrillation
      Description
      Symptomatic persistent atrial fibrillation lasting for over seven days at a time can be a difficult heart problem to treat effectively. Current catheter ablation approaches do not always achieve long-term success in patients. Sometimes, combined approaches of catheter ablation and procedures requiring surgical incisions into the chest are performed for patients with symptomatic persistent atrial fibrillation. A new study called the aMAZE trial is studying the benefit of performing ligation of a heart structure called the left atrial appendage using a minimally invasive method. Combining this method with pulmonary vein isolation using traditional catheter ablation may lead to better results in patients with persistent or long-standing persistent atrial fibrillation. The aMAZE trial is enrolling eligible patients to undergo percutaneous left atrial appendage suture ligation and then catheter ablation for their atrial fibrillation. Patients will be followed to analyze the benefits, complications, and overall outcomes of the procedures and to see if this new procedure may provide a better alternative for patients with persistent atrial fibrillation compared to existing methods that are currently used.
      Contact
      210-567-8692
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Expression of Interleukin-18, IL-18 Receptors and IL-18 Binding Protein in...
      Protocol No.
      HSC20050198H
      Official Title
      Expression of Interleukin-18, IL-18 Receptors and IL-18 Binding Protein in Myocardial Tissue
      Description
      Contact
      (210) 567-2878
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Genetics of Coronary Artery Disease in Alaska Natives
      Protocol No.
      HSC20000388H
      Official Title
      Genetics of Coronary Artery Disease in Alaska Natives
      Description
      Why some people get heart disease and others do not.
      Contact
      258-9710
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Identification and Analysis of Immunomodulatory Molecules From Leukocytes in...
      Protocol No.
      HSC20040268H
      Official Title
      Identification and Analysis of Immunomodulatory Molecules From Leukocytes in Patients with Hematologic Disorders and Healthy Volunteers
      Description
      Contact
      617-5300 x16777
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   IL-18 Expression in Human Cardiovascular Tissue and its Role in Left...
      Protocol No.
      HSC20070031H
      Official Title
      IL-18 Expression in Human Cardiovascular Tissue and its Role in Left Ventricular Hypertrophy and Congestive Heart Failure
      Description
      Contact
      210-567-2878
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Multicenter Registry for Peripheral Arterial Disease Interventions and...
      Protocol No.
      HSC20130375H
      Official Title
      Multicenter Registry for Peripheral Arterial Disease Interventions and Outcomes (XL PAD Registry)
      Description
      Excellence in Peripheral arterial disease (XL PAD) is an observational study to evaluate the “real world” effectiveness of using stent and non-stent based therapies among Peripheral Arterial Disease (Claudication symptoms or pain in legs due to blockages of blood supply to the legs) patients treated with Percutaneous Intervention (Balloon angioplasty or stenting) primarily focusing on Superficial Femoral Artery interventions.
      Contact
      210-567-2106
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Neutrophil Activation of the Oxidative Burst
      Protocol No.
      HSC19940484H
      Official Title
      Neutrophil Activation of the Oxidative Burst
      Description
      This study is a research project on the antibacterial function of white blood cells. We hope to learn how white blood cells work to prevent infection and how they respond after infection occurs. You are asked to participate in this research study because laboratory analysis of your white blood cell function in the test tube will be an important part of our attempts to improve understanding how these cells respond to infections.
      Contact
      210-562-4010
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Role of IL-18 in Aortic Aneurysms
      Protocol No.
      HSC20110130H
      Official Title
      Role of IL-18 in Aortic Aneurysms
      Description
      To investigate the expression levels of IL-18 (an inflammatory marker), it''s receptors IL-18Ra and b, and its natural inhibitor IL-18 binding protein (IL-18BP) in aortic aneurysms.
      Contact
      210-567-2878
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Severe Chronic Neutropenia International Registry Protocol
      Protocol No.
      HSC19960054H
      Official Title
      Severe Chronic Neutropenia International Registry Protocol
      Description
      Contact
      210-704-3405
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Understanding the Cardiovascular Benefits of the Anti-Diabetes Medication...
      Protocol No.
      HSC20180077H
      Official Title
      SGLT2 INHIBITORS, KETONES, & CARDIOVASCULAR BENEFIT CTMS 18-0009
      Description
      A recently published study (The EMPA-REG OUTCOME trial) showed that the antidiabetic medication empagliflozin reduced cardiovascular mortality and hospitalization for heart failure, resulting in the drug’s approval by the FDA for the treatment of type 2 diabetic patients with cardiovascular disease. However, the reasons why the medication achieved these benefits remains unknown. In diabetic patients, this medication has shown to increase ketone (the breakdown of fat) levels in blood. In this study, we will try to mimic this increase of fat break down and assess heart function with MRI and PET imaging technology.
      Contact
      210-358-7200
      Locations
      UT Health Science Center
      Learn More About This Study

       

  •   Immune System

    •   Genomics of immune mediated diseases
      Protocol No.
      HSC20160018H
      Official Title
      Genomics of Immune Mediated Diseases
      Description
      New diseases of the immune system can be discovered by studying the genetic makeup of patients with a strong family history. In addition to providing a diagnosis, genetic studies can suggest better treatments in some cases. We are looking for children with immune mediated symptoms, including immune deficiency, inflammatory symptoms such as fever, and episodes of swelling, with at least one close relative (parent or sibling) who has the same symptom(s) and another who is not affected. Blood samples will be taken and analyzed for genetic differences.
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Varicella zoster vaccine study (VERVE)
      Protocol No.
      HSC20160085H
      Official Title
      The Safety and Effectiveness of the VaricElla zosteR VaccinE (VERVE) in Anti-TNF Users
      Description
      This study will test the effectiveness of Zostavax, the shingles vaccine, in preventing shingles among people with arthritis who are taking biologic treatments, which include Remicade, Enbrel, Humira, Cimzia, or Simponi. Shingles causes painful blisters along the course of a nerve branches and in some cases may cause eye damage. Preventing shingles with vaccination is the focus of this clinical trial that will evaluate the safety and effectiveness of Zostavax. Patients with inflammatory arthritis taking biologics will be randomized to receive Zostavax or placebo. Six weeks later, they will return to see if they have developed defenses to the varicella-zoster virus, through blood analysis. The findings of the study will be used to formulate recommendations for the use of Zostavax in people receiving biologic therapy in patients with arthritis.
      Contact
      210-567-6853
      Locations
      UT Health Science Center
      Learn More About This Study

       

  •   Infections/ Infectious Diseases

    •   NF-Kappa B Activation by NADPH Oxidases
      Protocol No.
      HSC19949484H
      Official Title
      NF-Kappa B Activation by NADPH Oxidases (Project of a program entitled "Nuclear Factor Kappa B, Oxidative Stress and Aging)
      Description
      This study is a research project on the antibacterial function of white blood cells. We hope to learn how white blood cells work to prevent infection and how they respond after infection occurs.
      Contact
      210-562-4010
      Locations
      UT Health Science Center
      Learn More About This Study

       

  •   Lungs, Breathing and Bronchial

    •   CF-FC Study: A Long-Term Prospective Observational Safety Study of the...
      Protocol No.
      HSC20120208H
      Official Title
      CF-FC Study: A Long-Term Prospective Observational Safety Study of the Incidence of and Risk Factors for Fibrosing Colonopathy in US Patients with Cystic Fibrosis Treated with Pancreatic Enzyme Replacement Therapy: A Harmonized Protocol Across Sponsors CFFC-OB-11
      Description
      Registry Primary Objectives: The primary objective of this study is to quantify over a 10-year period the incidence of fibrosing colonopathy in US patients with CF treated with specific PERT (CREON®, PANCREAZE®, or ZENPEP®). Secondary Objectives: The secondary objective of this study is to quantify the association between potential risk factors and the development of fibrosing colonopathy in patients with CF.
      Contact
      210-704-4447
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Microparticles Generated by Cardiopulmonary Bypass.
      Protocol No.
      HSC20120097H
      Official Title
      Microparticles Generated by Cardiopulmonary Bypass.
      Description
      To obtain peripheral blood from normal volunteers to study the generation of microparticles.
      Contact
      210-562-5816
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   North American Cystic Fibrosis Foundation Patient Registry
      Protocol No.
      HSC20020383H
      Official Title
      North American Cystic Fibrosis Foundation Patient Registry
      Description
      By examining the health status of patients with cystic fibrosis annually, valuable information has (and will continue) to be gained about the trends in nutrition, medical problems, lung transplantation and bacterial colonization in patients with cystic fibrosis. Collection and analysis of this information (which is collected on every CF patient in North America) allows CF care teams to improve in their knowledge of the disease and to change the way they care for patients with CF appropriately.
      Contact
      562-5830
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Targeted Removal of Pro-Inflammatory Cells: an open label human pilot study...
      Protocol No.
      HSC20170199H
      Official Title
      Targeting Pro-Inflammatory Cells in Idiopathic Pulmonary Fibrosis: a Human Trial
      Description
      To reduce the abundance of pro-inflammatory cells over baseline within subjects following treatment with dasatinib and quercetin
      Locations
      UT Health Science Center
      Learn More About This Study

       

  •   Men's Health

    •   BBiomarkers and Clinical Data Associated with upgrading from low-grade...
      Protocol No.
      HSC20140367H
      Official Title
      Biomarkers and Clinical Parameters Associated with Gleason Score Upgrading
      Description
      This study is for men who have already been diagnosed with prostate cancer and have elected radical prostatectomy (removal of the prostate) as treatment. The study is on why less aggressive prostate cancer may sometimes develop into more aggressive prostate cancer and will enroll approximately 600 study participants, across all sites. Participants will undergo procedures prior to the surgery with possible long-term follow up participation lasting up to 10 years. Participants will be asked to sign a medical release form so we can request prostate biopsy pathology reports and biopsy slides and blocks in order to confirm a prostate cancer diagnosis. Participants will be asked to complete forms and questionnaires providing information regarding medical history, risk factors such as alcohol and smoking, race and ethnicity, and family history of prostate cancer. Following the medical history, trained research staff will draw blood samples for research purposes. Participants will be asked to complete a digital rectal exam prior to the surgery and provide a urine sample that will be tested for potential biomarkers associated with prostate cancer. We will request that blood, urine, and prostate tissue samples be stored in our central research repository. Materials collected in the repository may be used for future research associated with prostate cancer. Participants may be contacted for follow up information to determine disease progression, if any. Participants can withdraw from the study anytime.
      Contact
      210-567-0178
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Chemical and Environmental Intolerances
      Protocol No.
      HSC20150821H
      Official Title
      Toxicant Induced Loss of Tolerance: Research and Education
      Description
      The purpose of this research is to identify individuals who suffer from chemical intolerances and to look for potential environmental triggers that may be in their homes. Our goal is to offer practical solutions and determine if symptoms improve after implementing our team''s recommendations.
      Contact
      210-827-7681
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Effect of mTOR Inhibition and other Metabolism Modulating Interventions on...
      Protocol No.
      HSC20120304H
      Official Title
      Effect of mTOR Inhibition and other Metabolism Modulating Interventions on the Elderly: Immune, Cognitive, and Fuctional Consequences.
      Description
      A research study of the mechanisms that are affected by the mTOR inhibition by Rapamycin. Rapamycin is a drug approved by the US Food and Drug Administration (FDA) for human use that has shown to increase lifespan in laboratory animals. In human medicine, Rapamycin is used is an immunosuppressant drug used to prevent rejection in organ transplantation; it is especially useful in kidney transplants. mTOR controls growth of cells in your body. Rapamycin reduced mTOR effects. The researchers hope to learn how mTOR inhibition affects humans by looking at how the immune system that is altered in normal aging and mTOR inhibition by Rapamycin. The information gained from these experiments will aid in understanding how mTOR inhibition works in humans and will provide new and important information on changes in age-related immune system regulation.
      Contact
      210-497-7279
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Home based exercise and men with prostate cancer
      Protocol No.
      HSC20160604H
      Official Title
      Impact of a home-based exercise program on prognostic biomarkers in men with prostate cancer
      Description
      The purpose of this study is to determine the benefits of a home based exercise program on cancer progression in men with prostate cancer
      Contact
      210-567-0362
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Impact of Yoga as a Complementary Therapy in Patients Undergoing Radical...
      Protocol No.
      HSC20150406H
      Official Title
      Impact of Yoga As Complementary Therapy on Quality of Life, Pro-inflammatory, and Cellular Immune Biomarkers in Patients Undergoing Radical Prostatectomy: A Pilot Randomized-Controlled Trial
      Description
      The researchers hope to learn if yoga complementary therapy before and after prostate surgery would improve health-related quality of life, recovery of urinary continence and erectile function in patients who underwent prostate cancer surgery (i.e. radical prostatectomy).
      Contact
      210-551-0715
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Network Dysregulation Among Individuals with Co-Morbid Tinnitus and PTSD
      Protocol No.
      HSC20180524H
      Official Title
      Network Dysregulation Among Individuals with Co-Morbid Tinnitus and PTSD
      Description
      The purpose of this study is to determine the overlap of symptoms between posttraumatic stress disorder (PTSD) and tinnitus-related distress (ringing or buzzing in one or both ears). We will evaluate the overlap of symptoms by conducting assessments for psychological problems and tinnitus, as well as evaluate brain activity while undergoing a functional magnetic resonance imaging session (MRI). We also would like to know whether alleviating symptoms of PTSD would help decrease bothersome tinnitus. Everyone in this study will be treated for their PTSD with CPT. We will examine if tinnitus-related distress can also be decreased as a function of receiving therapy for PTSD, which is the focus of this study. The researchers hope to learn how the brain connectivity changes for male Veterans with both PTSD and tinnitus, after receiving therapy for PTSD.
      Contact
      210-562-6716
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Targeted Removal of Pro-Inflammatory Cells: an open label human pilot study...
      Protocol No.
      HSC20170199H
      Official Title
      Targeting Pro-Inflammatory Cells in Idiopathic Pulmonary Fibrosis: a Human Trial
      Description
      To reduce the abundance of pro-inflammatory cells over baseline within subjects following treatment with dasatinib and quercetin
      Locations
      UT Health Science Center
      Learn More About This Study

       

  •   Mouth and Tooth

    •   Incidence and Factors Associated with the Development and Severity of Oral...
      Protocol No.
      HSC20050218H
      Official Title
      Incidence and Factors Associated with the Development and Severity of Oral Mucositis in Patients Undergoing High Dose Chemotherapy and Peripheral Stem Cell Transplantation
      Description
      To prospectively evaluate the incidence and severity of oral mucositis in patients undergoing high dose chemotherapy and hematopoietic stem cell transplantation. To analyze patient-, disease- and transplant related factors in the development and severity of mucositis after high dose chemotherapy and hematopoietic stem cell transplantation.
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Rechargeable Infection-responsive Anticandidal Denture Materials
      Protocol No.
      HSC20120163H
      Official Title
      Rechargeable Infection-responsive Anticandidal Denture Materials
      Description
      To test the anticandidal drug binding and release kinetics as well as the cytotoxicities of the proposed long-term anticandidal denture materials
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Studies on Normal and Inflamed Dental Pulp. Subtitle: "NPY Regulation of...
      Protocol No.
      HSC20020071H
      Official Title
      Studies on Normal and Inflamed Dental Pulp. Subtitle: "NPY Regulation of Peripheral Human Nociceptors and Pain" and "peripheral Mechanisms of Opioid Analgesia".Subtitle: "Cannabinoid-Induced Desensitization of TRPV1 Receptors" Subtitle: Adrenergic Modulation of Trigeminal Nociceptors. Subtitle: Estrogen Modulation of Human Nociceptors
      Description
      A research study about the effect of medicines on nerves in teeth and how they react to inflammation.
      Contact
      210-567-3388
      Locations
      UT Health Science Center
      Learn More About This Study

       

  •   Muscle, Bone and Cartilage

    •   Placebo-Controlled Efficacy and Safety Study of Ataluren in Patients with...
      Protocol No.
      HSC20170289H
      Official Title
      A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED EFFICACY AND SAFETY STUDY OF ATALUREN IN PATIENTS WITH NONSENSE MUTATION DUCHENNE MUSCULAR DYSTROPHY AND OPEN-LABEL EXTENSION
      Description
      The main goals of this study are to obtain additional information on whether the actions of ataluren can slow disease progression
      Contact
      210-567-8222
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Varicella zoster vaccine study (VERVE)
      Protocol No.
      HSC20160085H
      Official Title
      The Safety and Effectiveness of the VaricElla zosteR VaccinE (VERVE) in Anti-TNF Users
      Description
      This study will test the effectiveness of Zostavax, the shingles vaccine, in preventing shingles among people with arthritis who are taking biologic treatments, which include Remicade, Enbrel, Humira, Cimzia, or Simponi. Shingles causes painful blisters along the course of a nerve branches and in some cases may cause eye damage. Preventing shingles with vaccination is the focus of this clinical trial that will evaluate the safety and effectiveness of Zostavax. Patients with inflammatory arthritis taking biologics will be randomized to receive Zostavax or placebo. Six weeks later, they will return to see if they have developed defenses to the varicella-zoster virus, through blood analysis. The findings of the study will be used to formulate recommendations for the use of Zostavax in people receiving biologic therapy in patients with arthritis.
      Contact
      210-567-6853
      Locations
      UT Health Science Center
      Learn More About This Study

       

  •   Nervous System

    •   A Randomized, Placebo-Controlled Trial to evaluate Lacosamide (Vimpat) as...
      Protocol No.
      HSC20150642H
      Official Title
      A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Study To Evaluate The Efficacy And Safety of Lacosamide As Adjunctive Therapy For Uncontrolled Primary Generalized Tonic-Clonic Seizures In Subjects With Idiopathic Generalized Epilepsy
      Description
      This study seeks to evaluate the safety and efficacy of Lacosamide (VImpat) as an add-on therapy for patients with Grand Mal/Generalized Tonic-Clonic seizures (GTCS), already taking 1-2 Anti-Epileptic medications and still experiencing 1 GTCS every 4-6 weeks.
      Contact
      210-567-8222
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Functional Connectivity in Partial Neocortical Epilepsy
      Protocol No.
      HSC20110063H
      Official Title
      Functional Connectivity in Partial Neocortical Epilepsy
      Description
      Our overall goal is to noninvasively examine how epilepsy results from brain reorganization after stroke, focusing on changes in connectivity and excitability. We will test the hypothesis that the seizure onset zone (SOZ), the region in the brain where seizure activity originates, is reorganized differently after stroke. We will use three populations of patients in our studies: Population 1: Patients with neocortical epilepsy of different etiologies including stroke; Population 2: Patients with past stroke, without epilepsy; Population 3: Age and health matched normal controls. The following specific aim will be pursued: To noninvasively study network reorganization that underlies epileptogenesis after cortical motor stroke. We hypothesize that the seizure onset zone (SOZ), where seizure activity originates, undergoes a different reorganization after stroke compared to seizure-neutral post-stroke tissue. We will use functional connectivity, which refers to how different regions of the brain are linked to each other and as measured using non-invasive MRI techniques, as a measure of circuit organization. We will compare the connectivity patterns of a population of patients who already have post-stroke epilepsy at the onset of the study with several patient groups including: patients with epilepsy of other etiologies, patients with chronic stroke without epilepsy, as well as with normal controls. A subtractive analysis will allow us to identify post-stroke epilepsy-specific connectivity changes. To accomplish this goal, we will measure the connectivity between regions of interest (ROI) in the peri-infarct zone (PIZ), which is where seizures are presumed to start from, and other regions in the cortical motor/sensory network. When possible, we will determine the location of the seizure onset zone (SOZ) and use it as a ROI for this analysis. In summary, using rsfMRI, we will measure functional connectivity of post-stroke brain motor networks and identify changes that could be linked to epilepsy. Our investigations could contribute to a better in vivo understanding of epilepsy-related changes after stroke, and may help develop biomarkers for post-stroke epileptogenesis.
      Contact
      210-567-8229
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Macrophage-mediated gene delivery of neurotrophic factors for Parkinson''s...
      Protocol No.
      HSC20120184H
      Official Title
      Macrophage-mediated gene delivery of neurotrophic factors for Parkinson''s disease
      Description
      Contact
      210-567-4627
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Tooth Fairy Study
      Protocol No.
      HSC20110313H
      Official Title
      Potential Risk Factors Associated with Autism Spectrum Disorders
      Description
      Participate in the Tooth Fairy Study! Our research team recently discovered that toxins such as plastics, pesticides and medications are stored in baby teeth as they are forming during pregnancy and shortly thereafter. The cause of autism is unknown; however, genetic and environmental factors are both likely involved. This study is being done to learn if children with autism have been exposed to more environmental toxins than typically-developing children and to learn if their genes are more vulnerable to the toxins. We are currently enrolling biological mothers of children with autism, their siblings AND mothers of children developing normally. Participants will fill out a survey regarding nutrition and exposures (~30 minutes), and donate their child’s baby teeth. To be eligible for this study… • You must be the biological mother of a child who is 2 years or older. • Your child must either have an established or suspected diagnosis of autism OR be a typically-developing child with no chronic medical problems • You must have a tooth from your child in good condition (not too worn or large cavities/crowns) To learn more about this study… Contact Lynne Heilbrun, MPH at heilbrun@UTHSCSA.edu.
      Contact
      210-274-4009
      Locations
      UT Health Science Center
      Learn More About This Study

       

  •   Other

    •   Bariatric Surgeries and Glucose Metabolism
      Protocol No.
      HSC20180070H
      Official Title
      Bariatric Surgeries and Glucose Metabolism
      Description
      This research study is being performed to answer specific questions about changes in glucose metabolism after weight-loss surgery. Insulin is the main hormone that controls the level of glucose (sugar) in your blood. Two most commonly performed weight-loss surgeries (bariatric surgery), gastric bypass surgery and sleeve gastrectomy, improve glucose control in patients with type 2 diabetes before any weight loss happens. The amount of insulin that your body makes after eating is increased after these surgeries. Evidence suggests that these surgeries increase gut hormones, which in turn can increase insulin levels. One of the gut hormones is called GLP-1 or “glucagon-like peptide 1”. Another is called GIP or “glucose-dependent insulinotropic peptide”. This study will determine the effects of bariatric surgery on blood glucose levels and insulin response that are mediated by gut hormones as well as neural activity. You may qualify to take part in this research study if you are between 18 and 80 years of age and you either had weight loss surgery or because you are serving as a healthy volunteer who did not have any gut surgery (control subject).
      Contact
      210-450-8696
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Chemical and Environmental Intolerances
      Protocol No.
      HSC20150821H
      Official Title
      Toxicant Induced Loss of Tolerance: Research and Education
      Description
      The purpose of this research is to identify individuals who suffer from chemical intolerances and to look for potential environmental triggers that may be in their homes. Our goal is to offer practical solutions and determine if symptoms improve after implementing our team''s recommendations.
      Contact
      210-827-7681
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Clinical Effectiveness Trial of In-Home Cognitive Processing Therapy for...
      Protocol No.
      HSC20140055H
      Official Title
      Clinical Effectiveness Trial of In-Home Cognitive Processing Therapy for Combat-Related PTSD
      Description
      This STRONG STAR research study will examine effective ways of delivering Cognitive Processing Therapy (CPT) for combat-related posttraumatic stress disorder (PTSD). CPT involves learning to recognize and challenge thoughts related to a traumatic experience and is typically done through face-to-face sessions in a mental health clinic. However, traveling into a clinic can be a potential barrier for some people. The goal of this study is to evaluate the effectiveness of administering CPT in one of the following treatment settings: 1) face-to-face in a clinic office, 2) face-to-face in the home setting, or 3) through telehealth (i.e., video sessions on your computer) in the home setting. Eligible participants are OIF/OEF/OND veterans with PTSD who reside in the San Antonio area.
      Contact
      210-562-6727
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Human Innate Immunity and Tuberculosis
      Protocol No.
      HSC20170315H
      Official Title
      Human Innate Immunity and Tuberculosis
      Description
      Tuberculosis is an infection that primarily affects the lungs and causes fever and weight loss. While some people exposed to the tuberculosis (TB) bacteria develop the disease others do not. An important step in our understanding of these different responses is to measure the response of immune cells to infection with the TB bacteria. This study will request blood to be collected from healthy individuals and individuals who have had a positive test result for TB.
      Contact
      (210) 258-9577
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Improving and Sustaining Delivery of CPT for PTSD in Mental Health Systems
      Protocol No.
      HSC20160045H
      Official Title
      Improving and Sustaining Delivery of CPT for PTSD in Mental Health Systems
      Description
      The purpose of the study is to compare the impact of two strategies to sustain and improve the delivery of an evidence-based psychotherapy for PTSD, cognitive processing therapy (CPT).
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Ketamine for Antidepressant-Resistant PTSD
      Protocol No.
      HSC20150550H
      Official Title
      Ketamine for Antidepressant-Resistant PTSD
      Description
      The purpose of this study is to examine the effectiveness of repeated doses of ketamine in Veterans and active duty military personnel with treatment-resistant posttraumatic stress disorder (PTSD). This study consists of three treatment groups, and participation will last a total of 8-weeks. Eligible participants include veterans and active-duty military personnel with PTSD who are able to attend approximately 16 study visits at SAMMC.
      Contact
      210-539-9422
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Mobile mindfulness training app for chronic pain patients
      Protocol No.
      HSC20180621H
      Official Title
      Evaluating a Mobile Mindfulness Training among Chronic Pain Patients Using Prescription Opioid CTMS#: CTMS 18-0117
      Description
      The purpose of this project is to explore the usefulness of a mobile mindfulness training, alongside standard of care, for individuals with chronic back and neck pain, in a four-week long study.
      Contact
      210-562-4682
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Network Dysregulation Among Individuals with Co-Morbid Tinnitus and PTSD
      Protocol No.
      HSC20180524H
      Official Title
      Network Dysregulation Among Individuals with Co-Morbid Tinnitus and PTSD
      Description
      The purpose of this study is to determine the overlap of symptoms between posttraumatic stress disorder (PTSD) and tinnitus-related distress (ringing or buzzing in one or both ears). We will evaluate the overlap of symptoms by conducting assessments for psychological problems and tinnitus, as well as evaluate brain activity while undergoing a functional magnetic resonance imaging session (MRI). We also would like to know whether alleviating symptoms of PTSD would help decrease bothersome tinnitus. Everyone in this study will be treated for their PTSD with CPT. We will examine if tinnitus-related distress can also be decreased as a function of receiving therapy for PTSD, which is the focus of this study. The researchers hope to learn how the brain connectivity changes for male Veterans with both PTSD and tinnitus, after receiving therapy for PTSD.
      Contact
      210-562-6716
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Prospective, randomized, double blind controlled pilot study to compare...
      Protocol No.
      HSC20120196H
      Official Title
      Prospective, randomized, double blind controlled pilot study to compare topical voriconazole to placebo as a pain reducing agent at skin donor sites
      Description
      Primary 1. The pain levels for donor site wounds treated with voriconazole will be less than the pain levels for donor site wounds treated with placebo. 2. Cutaneous levels of oxidized linoleic acid metabolites (OLAMs) collected by microdialysis probes will be less in donor sites treated with topical voriconazole as compared to donor sites treated with placebo.
      Locations
      UT Health Science Center
      Learn More About This Study

       

  •   Reproductive Health

    •   Chlamydia Trachomatis Proteomics-Profiling Immune Responses in Women with...
      Protocol No.
      HSC20070236H
      Official Title
      Chlamydia Trachomatis Proteomics-Profiling Immune Responses in Women at Reproductive Age
      Description
      A research study looking at factors in the blood that may be related to infertility (difficulty in becoming pregnant). We want to learn if your body has ever created an immune response (made factors that can fight infection or cause swelling or scarring inside the body) to certain factors that may cause infertility.
      Contact
      210-567-4924
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   The Impact of Prenatal Opioid Use on Maternal-Infant Dyad
      Protocol No.
      HSC20180057H
      Official Title
      The Impact of Prenatal Opioid Use on Maternal-Infant Dyad
      Description
      Opioid exposure during pregnancy may place babies at risk for developing neonatal abstinence syndrome. The purpose of this study is to explore the impact of prenatal opioid use on stress and physiological attunement in mother-baby dyads. We are recruiting opioid and non-opioid using pregnant women.
      Contact
      210-450-8294
      Locations
      UT Health Science Center
      Learn More About This Study

       

  •   Substance Abuse

    •   Computer Based Training in Cognitive Behavioral Therapy for Spanish-Speaking...
      Protocol No.
      HSC20160575H
      Official Title
      Computer Based Training in CBT for Spanish-Speaking Substance Users
      Description
      We are seeking Spanish speaking individuals currently in or seeking treatment for substance use. The purpose of this study is to test the effectiveness of adding a computer delivered web-based form of Cognitive Behavioral Therapy to treatment currently being received. You will be asked to attend approximately 12 visits with the researchers or study staff at UTHSCSA, in addition to 8 weekly treatment visits and encounters. If you are assigned to the CBT4CBT group, there will be up to 8 additional encounters on a web-based platform. These modules may be completed on your own time by logging in to the web-based platform (cbt4cbt.com) and will take approximately one hour to complete. Most people complete one module per week, and you may choose the order in which you complete them. It may be necessary for you to return to the hospital/clinic every week and after the treatment period, for 2 follow up visits.
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   PRESCRIPTION OPIOID RESEARCH STUDY FOR RECREATIONAL DRUG USERS
      Protocol No.
      HSC20180167H
      Official Title
      REDUCING THE ABUSE LIABILITY OF PRESCRIPTION OPIOIDS IN RECREATIONAL DRUG USERS: A PILOT STUDY
      Description
      This is a study of new drug combinations to reduce the abuse potential of opioid analgesics amongst recreational drug users. At the UT Pain Clinic the effect of these drug combinations will be studied. Questions will be asked about how the drug affected you.
      Contact
      210-567-4273
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   The Impact of Prenatal Opioid Use on Maternal-Infant Dyad
      Protocol No.
      HSC20180057H
      Official Title
      The Impact of Prenatal Opioid Use on Maternal-Infant Dyad
      Description
      Opioid exposure during pregnancy may place babies at risk for developing neonatal abstinence syndrome. The purpose of this study is to explore the impact of prenatal opioid use on stress and physiological attunement in mother-baby dyads. We are recruiting opioid and non-opioid using pregnant women.
      Contact
      210-450-8294
      Locations
      UT Health Science Center
      Learn More About This Study

       

  •   Urinary Tract and Kidney

    •   Assessment of Cognitive Function in Mexican Americans with End-Stage Renal...
      Protocol No.
      HSC20110429H
      Official Title
      Assessment of Cognitive Function in Mexican Americans with End-Stage Renal Disease Receiving Hemodialysis (ACME)
      Description
      The purpose of this study to explore the health-related quality of life and to evaluate cognitive function status in Mexican Americans who are on hemodialysis because they are diagnosed with end-stage renal disease (ESRD) due to type 2diabetes (T2D).
      Contact
      210-508-2889
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Urinary Stone Biorepository
      Protocol No.
      HSC20120213H
      Official Title
      Urinary Stone Biorepository
      Description
      We propose to create the Urinary Stone Biorepository for collection, storage and distribution of urinary stones and pertinent health information to use as a resource for future research examining areas such as novel methods of fragmenting kidney stones or the relationships between stone composition and clinical risk factors
      Locations
      UT Health Science Center
      Learn More About This Study

       

  •   Women's Health

    •   Chemical and Environmental Intolerances
      Protocol No.
      HSC20150821H
      Official Title
      Toxicant Induced Loss of Tolerance: Research and Education
      Description
      The purpose of this research is to identify individuals who suffer from chemical intolerances and to look for potential environmental triggers that may be in their homes. Our goal is to offer practical solutions and determine if symptoms improve after implementing our team''s recommendations.
      Contact
      210-827-7681
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Chlamydia Trachomatis Proteomics-Profiling Immune Responses in Women with...
      Protocol No.
      HSC20070236H
      Official Title
      Chlamydia Trachomatis Proteomics-Profiling Immune Responses in Women at Reproductive Age
      Description
      A research study looking at factors in the blood that may be related to infertility (difficulty in becoming pregnant). We want to learn if your body has ever created an immune response (made factors that can fight infection or cause swelling or scarring inside the body) to certain factors that may cause infertility.
      Contact
      210-567-4924
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Targeted Removal of Pro-Inflammatory Cells: an open label human pilot study...
      Protocol No.
      HSC20170199H
      Official Title
      Targeting Pro-Inflammatory Cells in Idiopathic Pulmonary Fibrosis: a Human Trial
      Description
      To reduce the abundance of pro-inflammatory cells over baseline within subjects following treatment with dasatinib and quercetin
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   The Impact of Prenatal Opioid Use on Maternal-Infant Dyad
      Protocol No.
      HSC20180057H
      Official Title
      The Impact of Prenatal Opioid Use on Maternal-Infant Dyad
      Description
      Opioid exposure during pregnancy may place babies at risk for developing neonatal abstinence syndrome. The purpose of this study is to explore the impact of prenatal opioid use on stress and physiological attunement in mother-baby dyads. We are recruiting opioid and non-opioid using pregnant women.
      Contact
      210-450-8294
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   Tooth Fairy Study
      Protocol No.
      HSC20110313H
      Official Title
      Potential Risk Factors Associated with Autism Spectrum Disorders
      Description
      Participate in the Tooth Fairy Study! Our research team recently discovered that toxins such as plastics, pesticides and medications are stored in baby teeth as they are forming during pregnancy and shortly thereafter. The cause of autism is unknown; however, genetic and environmental factors are both likely involved. This study is being done to learn if children with autism have been exposed to more environmental toxins than typically-developing children and to learn if their genes are more vulnerable to the toxins. We are currently enrolling biological mothers of children with autism, their siblings AND mothers of children developing normally. Participants will fill out a survey regarding nutrition and exposures (~30 minutes), and donate their child’s baby teeth. To be eligible for this study… • You must be the biological mother of a child who is 2 years or older. • Your child must either have an established or suspected diagnosis of autism OR be a typically-developing child with no chronic medical problems • You must have a tooth from your child in good condition (not too worn or large cavities/crowns) To learn more about this study… Contact Lynne Heilbrun, MPH at heilbrun@UTHSCSA.edu.
      Contact
      210-274-4009
      Locations
      UT Health Science Center
      Learn More About This Study

       

  •   Wounds and Injuries

    •   Open Globe Injury Registry
      Protocol No.
      HSC20130270H
      Official Title
      Open Globe Injury Registry
      Description
      To learn about outcomes in open globe injuries. Open Globe Eye injury is defined as a traumatic breakdown in the integrity of the wall of the eye.
      Contact
      210-567-8409
      Locations
      UT Health Science Center
      Learn More About This Study

       

    •   VA Polytrauma Rehabilitation Center (PRC) Traumatic Brain Injury Model...
      Protocol No.
      HSC20140208H
      Official Title
      VA Polytrauma Rehabilitation Center (PRC) Traumatic Brain Injury Model Systems (TBIMS) at the South Texas Veterans Health Care System - Audie Murphy PRC
      Description
      We are searching for interested Veterans and active service members to participate in a longitudinal study of the short and long-term outcomes related to traumatic brain injury. By understanding those outcomes we hope to improve the quality of life of individuals and families affected by TBI.
      Contact
      210-617-5300
      Locations
      UT Health Science Center
      Learn More About This Study